ORIGINAL_ARTICLE
Comparison Between Intracoronary and Intravenous Eptifibatide and Intracoronary Reteplase in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial
Background: Despite the benefits of primary percutaneous coronary intervention (PPCI), myocardial perfusion after treatment remains disrupted in some patients. The utility of glycoprotein IIb/IIIa inhibitors and reteplase during the intervention is indeterminate.Methods: We designed a randomized clinical trial to compare intravenous (IV) and intracoronary (IC) eptifibatide and reteplase in 144 patients with ST-elevation myocardial infarction scheduled for PPCI. The primary outcome was coronary blood flow according to the TIMI flow grade (TFG) before and after PPCI. The secondary outcomes were the differences between ST-segment resolution, diastolic left ventricular dysfunction, left ventricular ejection fraction, mitral regurgitation, CK-MB levels, and hemoglobin levels before and after PPCI.Results: TFG III was achieved in all patients (100%) in the control and reteplase groups. TFG III was seen in 32 (88.9%) and 33 (91.7%) patients in the IV and IC eptifibatide groups, respectively. TFG II was reported in 4 (11.1%) and 3 (8.3%) patients in the IV and IC eptifibatide groups in the same order. Postprocedural TFG was not significantly different between the groups. There was a significant increase in the CK-MB level in the reteplase group compared with the other groups (P<0.05). Postprocedural hemoglobin, ST resolution, and ejection fraction were not significantly different between the groups. Reteplase was associated with a significant improvement in diastolic left ventricular dysfunction compared with the control group (odds ratio, 0.31; P=0.02). No difference was shown in the development of mitral regurgitation between the 4 groups.Conclusions: Neither IV nor IC eptifibatide nor reteplase was associated with improvements in the coronary blood flow as determined by TFG, ST resolution, and ejection fraction. (Iranian Heart Journal 2022; 23(1): 6-16)
http://journal.iha.org.ir/article_142593_ac1215a7b2182f946aea83bd367edf60.pdf
2022-01-01
6
16
Primary percutaneous coronary intervention
Eptifibatide
Reteplase
intravenous
Intracoronary
Salman
Nikfarjam
1
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.
AUTHOR
Mostafa
Zadkamali
2
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.
AUTHOR
Arsalan
Salari
3
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.
AUTHOR
Maryam
Shakiba
4
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.
AUTHOR
Mahboubeh
Janesar Hoseinie
5
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.
AUTHOR
Fardin
Mirbolouk
mirboloukfardin@gmail.com
6
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.
LEAD_AUTHOR
Iversen A, Galatius S, Jensen JS. The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percutaneous coronary intervention; intravenous versus intracoronary. Curr Cardiol Rev 2008; 4: 293-9. doi: 10.2174/157340308786349480.
1
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. The Lancet 1997; 349: 1498-1504. doi: 10.1016/S0140-6736(96)07492-2
2
Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155-2165. doi:10.1056/NEJMoa0908610
3
Smilowitz NR, Feit F. The History of primary angioplasty and stenting for acute myocardial infarction. Curr Cardiol Rep 2016; 18: 5. doi: 10.1007/s11886-015-0681-x.
4
Antman EM, Anbe DT, Armstrong PW,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 2004; 44: 671-719. doi: 10.1161/01.CIR.0000134791.68010.FA
5
Vecchio S, Varani E, Chechi T, et al. Coronary thrombus in patients undergoing primary PCI for STEMI: Prognostic significance and management. World J Cardiol 2014; 6: 381. doi: 10.4330/wjc.v6.i6.381
6
Pellicori P, Torromeo C, Barillà F, et al. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function. Cardiol J 2013; 20: 310-7. doi: 10.5603/CJ.2013.0077.
7
Henriques J, Zijlstra F, Ottervanger J, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23: 1112-7. https://doi.org/10.1053/euhj.2001.3035
8
Napodano M, Pasquetto G, Saccà S, et al. Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1395-1402. doi: 10.1016/s0735-1097(03)01041-6
9
Erdim R, Erciyes D, Görmez S, et al. Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention/Primer perkütan koroner girisim uygulanan hastalarda tirofibanin intrakoroner ve intravenöz bolus dozlarinin karsilastirilmasi. Anadulu Kardiyoloji Dergisi: AKD 2010; 10: 340. doi: 10.5152/akd.2010.093.
10
Limbruno U, Micheli A, De Carlo M, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003; 108(2): 171-6. doi: 10.1161/01.CIR.0000079223.47421.78
11
Sanati HR, Zahedmehr A, Firouzi A, et al. Intracoronary versus Intravenous eptifibatide during percutaneous coronary intervention for acute ST-segment elevation myocardial infarction; a randomized controlled trial. Cardiovasc Interv Ther 2017; 32: 351-7. doi: 10.1007/s12928-016-0418-9
12
Investigators PT. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-443. doi: 10.1056/NEJM199808133390704
13
O'gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: 485-510. doi.org/10.1161/CIR.0b013e3182742c84.
14
Namazi MH, Safi M, Vakili H, et al. Comparison between intracoronary abciximab and intravenous eptifibatide administration during primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. JTehran Heart Cent 2013; 8:132.
15
Esfandi A, Fotouhi M, Allami A, et al. Comparison between the outcomes of intracoronary and intravenous administration of eptifibatide during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction. J Atheroscler Thromb 2016;23:465-476. doi: 10.5551/jat.30965
16
Morteza Safi M, Hosein Vakili M, Habibollah Saadat M, et al. The comparison of intracoronary versus intravenous eptifibatide administration during primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. Life Sci J 2012;9.
17
Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 2010;121:784-791. doi: 10.1161/CIRCULATIONAHA.109.882746
18
Thiele H, Wöhrle J, Neuhaus P, et al. Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 2010;159:547-554. DOI: 10.1016/j.ahj.2009.12.038
19
Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010;122:2709-2717. doi: 10.1161/CIRCULATIONAHA.110.002741
20
Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57. doi: 10.1161/CIRCULATIONAHA.107.747642
21
Elbadawi A, Elgendy IY, Megaly M, et al. Meta-Analysis of Randomized Trials of Intracoronary Versus Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Am J Cardiol 2017;120:1055-1061. DOI: 10.1016/j.amjcard.2017.06.040
22
Kelly RV, Crouch E, Krumnacher H, Cohen MG, et al. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. Cathet Cardiovasc interv 2005;66:327-332. DOI: 10.1002/ccd.20521
23
Triantafyllou K, Metaxopoulos P, Babalis D. Primary percutaneous coronary intervention of an unprotected left main using mini‐crush drug‐eluting stents facilitated by intracoronary reteplase. Cathet Cardiovasc interv 2011;77:515-521. doi: 10.1002/ccd.22815
24
ORIGINAL_ARTICLE
Development of a New Framework for Health Assessment in Patients With Coronary Artery Disease by Using microRNA-197 in Iranian Adults
Background: Coronary artery disease (CAD) refers to stenosis or obstruction in a part or all of a coronary artery due to atherosclerosis or clotting. This study aimed to evaluate the possible efficacy of the serum microRNA-197 (miR-197) as an indicator of diagnosis in patients with CAD. Methods: In this study, 100 patients with CAD who had angiography and vascular transplantation were selected and evaluated. The expression level of miR-197 was determined via the real-time RT-PCR technique and the SYBR Green method. For the analysis of the miRNA expression level and the significance of the patient sample, the t test was used. Additionally, the Pearson correlation coefficient test was utilized to determine the relationship between the expression levels of miRNAs and CAD severity. Results: A positive correlation was observed between miR-197 expression and CAD severity. The average expression of 0.78 in the control sample was increased to 2.76 according to the severity of involvement in the patient. In other words, the relative expression of miR-197 in the CAD + group was significantly increased compared with the control group (P<0.004). Conclusions: It appears that miR-197 can be considered an indicator of coronary endothelial cell function, and it is possible to use it as a biomarker for the prognosis, control, or treatment of CAD. (Iranian Heart Journal 2022; 23(1): 17-24)
http://journal.iha.org.ir/article_142595_3af2fce99e7c0bc27575e8015192bc44.pdf
2022-01-01
17
24
miR-197
Coronary Artery Disease
Real-Time RT-PCR
U6 snRNA
Shahram
Zehtabian
rosagol1343@gmail.com
1
Department of biology, Faculty of Biological Sciences, Islamic Azad University, North Tehran Branch, Tehran, IR Iran.
AUTHOR
Reza
Alibakhshi
ralibakhshiy@gmail.com
2
Department of Medical Genetics, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
LEAD_AUTHOR
Seyed-Yousef
Seyedena
y.seyedena@yahoo.com
3
Department of biology, Faculty of Biological Sciences, Islamic Azad University, North Tehran Branch, Tehran, IR Iran.
AUTHOR
Ali-Reza
Rai
alireza_rai@yahoo.com
4
Research and Educational Center, Imam Ali Cardiovascular Hospital, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Kanuri SH, Ipe J, Kassab K, Gao H. Next generation MicroRNA sequencing to identify coronary artery disease patients at risk of recurrent myocardial infarction. Atherosclerosis. 2018 Oct 3;278:232-239. doi: 10.1016/0002-9149(63)90064-X. [PubMed: 16141261].
1
Mozaffarian, E.J. Benjamin, A.S. Heart disease and stroke Statistics-2016 update: a report from the American heart association. Circulation, 133 (2016) e38-360. doi:10.1016/0002-9343(77)90423-5. [PubMed: 20961243].
2
Christian Albus, Jörg Barkhausen. The Diagnosis of Chronic Coronary Heart Disease. Dtsch Arztebl Int. 2017 Oct; 114(42):712–719. doi:10.1161/01.CIR.67.1.134.[PubMed: 25205802].
3
Albus, C; Barkhausen, J . The Diagnosis of Chronic Coronary Heart Disease. Dtsch Arztebl Int 2017; 114(42): 712-9. doi: 10.1161/CIRCULATIONAHA.112.130153. [PubMed: 21639811].
4
Caterina Catalanotto, Carlo Cogoni. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int J Mol Sci. 2016 Oct; 17(10): 1712. doi:10.1093/omcr/omw036. [PubMed: 22391581].
5
Hongyu Liu, Cheng Lei, Qin He. Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Molecular Cancer2018; 17:64. doi:10.2353/ajpath.2006.050646. [PubMed Central: PMC4169002].
6
Mihailescu R. Gene expression regulation: lessons from noncoding RNAs. RNA. 2015 Apr; 21(4):695-6. doi:10.1055/s-2005-872844. [PubMed Central: PMC4060354].
7
Christian Schulte, Simon Molz, Sebastian Appelbaum. miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease. PLoS One. 2015 Dec 31; 10(12). doi:10.1242/jcs.184770. [PubMed: 15673802].
8
Lerman G, Sharon M, Leibowitz-Amit R, Sidi Y, Avni D. The crosstalk between IL-22 signaling and miR-197 in human. PLoS kOne. 2014 Sep 10;9(9). doi:10.1097/GIM.0b013e31820ad795. [PubMed: 16565504].
9
Huamin Wang,Xiaoping Su,Mingjin Yang,Taoyong Chen,Jin Hou,Nan Li. Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma. Oncoimmunology. 2015 Jun 4; 4(10):e1031440. doi:10.1001/jama.2009.371. [PubMed: 18377432].
10
Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, De Maria R. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 2014 May; 21(5):774-82. doi:10.1002/mus.23517. [PubMed: 16217705].
11
Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018 Apr 25; 10(438). doi:10.14503/THIJ-13-3896. [PubMed: 21415759].
12
Jia HL, Liu CW, Zhang L, Xu WJ. Sets of serum exosomal microRNAs as candidate diagnostic biomarkers for Kawasaki disease. Sci Rep. 2017 Mar 20; 7:44706. doi: 10.4103/0189-7969.187732. [PubMed: 12084876].
13
McManus DD, Rong J, Huan T, Lacey S. Messenger RNA and MicroRNA transcriptomic signatures of cardiometabolic risk factors. BMC Genomics. 2017 Feb 8;18(1):139. doi:10.14503/THIJ-15-5450. [PubMed: 23168931].
14
Tang T, Cheng Y, She Q, Jiang Y, Chen Y, Yang W, Li Y. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother. 2018 Nov; 107:338-346. doi:10.1093/eurheartj/ehi471. [PubMed: 22695892].
15
Lu X, Liu Z, Ning X, Huang L, Jiang B. The Long Noncoding RNA HOTAIR Promotes Colorectal Cancer Progression by Sponging miR-197. Oncol Res. 2018 Apr 10; 26(3):473-481. doi:10.4244/EIJV8I1A20. [PubMed: 28638575].
16
Zhang Y, Huang S, Li P, Chen Q, Li Y. Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1 cells in vitro by down-regulating the PCSK1/3. Cancer Lett. 2018 Sep 1;431:190-200. doi:10.3978/j.issn.2225-319X.2015.02.05. [PubMed: 30393640].
17
Orlicka-Plocka M, Gurda D. Circulating microRNAs in cardiovascular diseases. Acta Biochim Pol.2016;63(4): 725-729. doi: 10.1016/j.jjcc.2015.09.009. [PubMed: 28627787].
18
Wei-Ping Tien, Gareth Lim. SYBR green-based one step quantitative real-time polymerase chain reaction assay for the detection of Zika virus in field-caught mosquitoes. Parasit Vectors. 2017; 10: 427. doi:10.1002/ajmg.a.38320. [PubMed: 22457381].
19
Marilia Farignoli, William Marciel. Evaluation and optimization of SYBR Green real-time reverse transcription polymerase chain reaction as a tool for diagnosis of the Flavivirus genus in Brazil. Rev. Soc. Bras. Med. 2016; 167-198. doi:10.1016/j.spen.2006.06.004. [PubMed: 15977643].
20
ORIGINAL_ARTICLE
Comparison of the One-Year Outcome Between Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease
Background: Our study aimed to compare the 1-year therapeutic outcome between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD). Methods: This retrospective cohort study was conducted on 150 patients with multivessel CAD who underwent CABG or PCI in Imam Ali Cardiovascular Center, Kermanshah, Iran, between March 2017 and March 2019. Data were collected using a checklist developed based on the study objectives. Differences between subgroups were assessed by using the independent t test and the χ2 test (or the Fisher exact test). A multivariate binary logistic regression model was used to determine factors associated with referral to CABG or PCI. Results: The mean age was 63.48 (SD=9.73) years in the PCI group and 60.54 (SD=10.85) years in the CABG group (P=0.741). The CABG group was more likely to have left main disease (16.6% vs 0%; P<0.001). The PCI group was more likely to take an antiplatelet (viz, clopidogrel) and nitrates, whereas the CABG group was more likely to take antihypertensives (angiotensin receptor blockers) and anticoagulants (viz, rivaroxaban and warfarin) (P<0.05). The CABG had significantly higher rates of major bleeding (P=0.003) and arrhythmia (P=0.045) than the PCI group. There was a significant difference in the mortality between the 2 treatment groups (9.3% of the CABG group vs 1.3% of the PCI group; P=0.029). Left main disease was associated with an increased odds of referral to CABG (OR=0.02; P=0.015). Conclusions: PCI was associated with a lower adverse clinical outcome than CABG in patients with multivessel CAD. (Iranian Heart Journal 2022; 23(1): 25-33)
http://journal.iha.org.ir/article_142596_8927ddb901db11f3d57302de3be48a7c.pdf
2022-01-01
25
33
Coronary artery bypass grafting
Coronary Artery Disease
Iran
outcome
ANGIOPLASTY
Mohammed
Rouzbahani
sepehr.amiri1398@gmail.com
1
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Zahra
Shirazinezhad
zahra.shirazinezhad@gmail.com
2
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Yahya
Salimi
babakhany_maryam@gmail.com
3
Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Parisa
Janjani
parisa.janjan@gmail.com
4
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Nahid
Salehi
nahid.salehi@gmail.com
5
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Alireza
Rai
alireza.rai@gmail.com
6
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Javad
Azimivaghar
javad.azimivaghar@gmail.com
7
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Arsalan
Naderipour
arsalan.naderipour@gmail.com
8
Department of Emergency Medicine, School of Paramedics, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Somayeh
Shirazinezhad
somayeh.shirazinezhad@gmail.com
9
Department of Radiology, Isfahan University of Medical Sciences, Isfahan, IR Iran.
AUTHOR
Etrat
Javadi rad
javadirad@gmail.com
10
Clinical Research Development Center of Imam Khomeini Hospital, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
AUTHOR
Reza
Heidari moghadam
heidary@kums.ac.ir
11
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
LEAD_AUTHOR
Shyu K-G, Wu C-J, Mar G-Y, Hou CJ-Y, Li A-H, Wen M-S, et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndromed observations from the Taiwan ACS full spectrum registry. Acta Cardiol Sin 2011; 27: e44.
1
Feeman Jr W. Risk factors versus inflammation in atherothrombotic disease. Circulation 2002; 106: e31.
2
Shemirani H, Separham K. The relative impact of smoking or Hypertension on severity of premature coronary artery disease. 2007.
3
Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsai T, et al. Acute myocardial infarction in the young—The University of Michigan experience. American heart journal 2002; 143: 56-62.
4
Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC: Cardiovascular Interventions 2010; 3: 1059-67.
5
Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. Journal of the American College of Cardiology 2001; 37: 51-8.
6
Frye RL, Alderman EL, Andrews K, Bost J, Bourassa M, Chaitman BR, et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) investigators. New England Journal of Medicine 1996; 335: 217-25.
7
Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. The Lancet 1998; 352: 1419-25.
8
Investigators BARI. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. New England Journal of Medicine 1996; 335: 217-25.
9
Participants CT. First-year results of CABRI (coronary angioplasty versus bypass revascularisation investigation). The Lancet 1995; 346: 1179-84.
10
Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). The American journal of cardiology 2014; 114: 555-61.
11
Becher T, Baumann S, Eder F, Perschka S, Loßnitzer D, Fastner C, et al. Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary intervention with the Impella 2.5 device. European Heart Journal: Acute Cardiovascular Care 2019; 8: 360-8.
12
Gunn J, Kuttila K, Kiviniemi T, Ylitalo A, Biancari F, Juvonen T, et al. Outcome after coronary artery bypass surgery and percutaneous coronary intervention in patients with atrial fibrillation and oral anticoagulation. Annals of medicine 2014; 46: 330-4.
13
Rodriguez A, Boullon F, Perez-Baliño N, Paviotti C, Liprandi MIS, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. Journal of the American College of Cardiology 1993; 22: 1060-7.
14
Hällberg V, Palomäki A, Lahtela J, Voutilainen S, Tarkka M, Kataja M. Associations of metabolic syndrome and diabetes mellitus with 16-year survival after CABG. Cardiovascular diabetology 2014; 13: 25.
15
Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. Jama 2013; 310: 1581-90.
16
Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary Artery Bypass Grafting vs Percutaneous Coronary Intervention and Long-term Mortality and Morbidity in Multivessel Disease: Meta-analysis of Randomized Clinical Trials of the Arterial Grafting and Stenting Era. JAMA Internal Medicine 2014; 174. doi: 10.1001/jamainternmed.2013.12844
17
Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT, Isom OW, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology 1999; 33: 63-72.
18
Kapur A, Bartolini D, Finlay MC, Qureshi AC, Flather M, Strange JW, et al. The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease. Journal of Cardiovascular Medicine 2010; 11: 26-33.
19
Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. Journal of the American College of Cardiology 2010; 55: 432-40.
20
Mohr FW, Morice M-C, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. The lancet 2013; 381: 629-38.
21
Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Journal of the American College of Cardiology 2015; 65: 2496-507.
22
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus eluting stents versus coronary artery bypass graft surgery for patients with diabetes mellitus and multivessel disease. Circulation: Cardiovascular Interventions 2015; 8: e002626.
23
Shiomi H, Morimoto T, Hayano M, Furukawa Y, Nakagawa Y, Tazaki J, et al. Comparison of long-term outcome after percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). The American journal of cardiology 2012; 110: 924-32.
24
Fink N, Nikolsky E, Assali A, Shapira O, Kassif Y, Barac YD, et al. Revascularization strategies and survival in patients with multivessel coronary artery disease. The Annals of thoracic surgery 2019; 107: 106-11.
25
ORIGINAL_ARTICLE
Discharge Against Medical Advice in the Emergency Department
Background: Discharge against medical advice (DAMA) is a process during which the patient leaves the hospital voluntarily without completing the course of treatment, which can indicate a significant problem. The present study was conducted in one of the hospitals of Tehran to identify the causes of DAMA and design its dashboard.
Methods: The present descriptive cross-sectional study examined the causes of DAMA in 2018 in a hospital in Tehran. Data were collected through a checklist prepared by the accreditation office. The collected data were inserted into QlikView software to design the dashboard.
Results: The results demonstrated that the prevalence of DAMA from the hospital under study was 0.7% in the outpatient department and 0.25% in the inpatient department compared with the total number of patients discharged in these departments. The most common reasons for DAMA were, respectively, unwillingness to undergo surgery or procedures and financial problems.
Conclusions: The findings allow hospital managers to take measures aimed at lessening DAMA and, thus, side effects, returns to the hospital, and additional costs. DAMA is a multidimensional phenomenon and is subject to several factors. Therefore, predicting the rate of DAMA and its determining factors can play an effective role in its control. (Iranian Heart Journal 2022; 23(1): 34-41)
http://journal.iha.org.ir/article_142597_365c83ca46a7066800afd5f331800e88.pdf
2022-01-01
34
41
Patient Discharge
Emergency Service
Hospital
patients
patient care management
Mahnaz
Mayelafshar
mahnazmayelafshar@yahoo.com
1
Department of Health Services Administration, Sciences, and Research, Islamic Azad University, Tehran, IR Iran.
AUTHOR
Feridoun
Noohi
fnoohib@yahoo.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Leila
Riahi
l.riahi@srbiau.ac.ir
3
Department of Health Services Administration, Sciences, and Research, Islamic Azad University, Tehran, IR Iran.
LEAD_AUTHOR
Anise
Nikravan
anisnik7@gmail.com
4
Department of Health Services Administration, Sciences, and Research, Islamic Azad University, Tehran, IR Iran.
AUTHOR
M, khanmohamadian, S,; 2019. Reception service at health centers,. Memar pour, M, Heidari Publications, Tehran. pp 110 [Book in Persian].
1
Hwang SW, Li J, Gupta R, Chien V & Martin RE. What happens to patients who leave hospital against medical advice? Canadian Medical Association Journal 2003; 168(4): 417-20.
2
Shafaghat, T- Rahimi Zarchi, M , Kavosi Z, Ayoubian A, Study of the Causes of Discharge against Medical Advice in a Hospital of Shiraz University of Medical Sciences,Payavard salammat journal. 2017:11(1), 31-42 [in Persian].
3
El-Metwally, A, Suliman Alwallan, N, Amin Alnajjar, A, Zahid, N , Alahmary, K, Toivola, P. Discharge against Medical Advice (DAMA) from an Emergency Department of a Tertiary Care Hospital in Saudi Arabia, Hindawi Emergency Medicine International, 2019:1-6.
4
Adefemi SA, Adeleke IT, Gara P, Abdul Ghaney OO, Omokanye SA & Jimoh Yusuf AM. The rate, reasons and predictors of hospital discharge against medical advice among inpatients of a tertiary health facility in North-central Nigeria. American Journal of Health Research 2014; 3(1): 11-6.
5
Jimoh BM, Anthonia OC, Chinwe I, Oluwafemi A, Ganiyu A, Haroun A, et al. Prospective evaluation of cases of discharge against medical advice in Abuja, Nigeria. The Scientific World Journal 2015; 2(1): 1-4.
6
Somasetia DH, Isman S & Wonoputri N. Discharge against medical advice in pediatric intensive care unit and subsequent International Journal of Integrated Health Sciences 2015; 3(1): 7-10.
7
Rahimi A & Khabbaz Zadah F. Reasons for discharge against medical advice: A study of a general hospital in Iran. Iranian Journal of Pediatrics 2014; 24(2): 79-84.
8
Kazemi M, Vazirinejad R, Soleimani MR, Ostadebrahimi H & Ayubipour N. Assessment of the incidence and reasons of discharge against medical advice in the hospitals of Rafsanjan University of Medical sciences in 2012-2013. Community Health Journal 2014; 8(3): 64-72[in Persian].
9
Mohseni M, Alikhani M, Tourani S, Azami Aghdash S, Royani S & Moradi-Joo M. Rate and causes of discharge against medical advice in Iranian hospitals: A systematic review and meta-analysis. Iranian Journal of Public Health 2015; 44(7): 902-12.
10
Pouragha B, Rajaee R, Najafi M. Evaluation of Discharge Against Medical Advice in Victims of Traffic Accidents at the Emergency Department: A case study. Evidence Based Health Policy, Management & Economics. 2018; 2(3): 202-7.
11
Mayelafshar, M, Noohi, F, Riahi, L, Nikravan. A, S. Key performance indicators of emergency department: A literature re-view; Cardiovascular Nursing Journal 8 (1) 2020: 10-19[in Persian].
12
Eckerson W. Performance Dashboards: Measuring, Monitoring, and Managing Your Business, Second ed. Hoboken: John Wiley & Sons; 2011. pp. 29, 1-318.
13
Pour Karimi SHA, Mohseni Saravi B, Bagherian Farahabbadi E, Zamanfar D, Fallah M & Asadi Abokheily M. Studying the rate and causes of discharge against medical advice in hospitals affiliated to Mazandaran university of medical sciences. Journal of the Academy of Medical Science of Bosnia and Herzegovina 2014; 26(3): 203-7.
14
Estebsari F, Dastoorpoor M, Mosavi Esfahani H, Mostafaie D, The Causes of Discharge against Medical Advice from the Emergency Department of a Teaching Hospital of Tehran in 2016,3(5).267-276[In Persian].
15
Najafpour Zh, Jafari MR, Hatamizadeh M, Rahimi S, Bigdeli Z, Homauni A. An Analysis of the Factors Affecting Discharge Against Medical Advices: A Case- Control Study in a Treatment- Teaching Hospital. Manage Strat Health Syst 2017; 2(1):39-47.
16
Malekzadeh R, Araghian Mojarad F, Amirkhanlou A, Sarafraz S & Salmanpour M. Causes of discharge against medical advice in hospitals affiliated with Mazandaran university of medical sciences, 2014. Journal of Mazandaran University of Medical Sciences 2016; 26(140): 95-102[in Persian].
17
Manouchehri J, Goodarzynejad H, Khoshgoftar Z, Sheikh Fathollahi M & Aghamohammadi Abyaneh M. Discharge against medical advice among inpatients with heart disease in Iran. Journal of Tehran University Heart Center 2012; 7(2): 72-7. [In Persian]
18
Roodpeyma SH & Eshagh Hoseyni SA. Discharge of children from hospital against medical advice. World Journal of Pediatrics 2010; 6(4): 353-6.
19
Kariman H, Khazaei AR, Shahrami A & Hatamabadi HR. Dealing with discharge against medical advice in emergency Journal of Basic and Applied Scientific Research 2013; 3(7): 785-91.
20
Noohi K, Komsari S, Nakhaee N & Yazdi Feyzabadi V. Reasons for discharge against medical advice: A case study of emergency departments in Iran. International Journal of Health Policy and Management 2013; 1(2): 137-42.
21
Mokhtari L, Korami Marekani A, Madadi M. Studying the Rate and Causes of Being Discharged Against Medical Advice in Inpatient and Outpatient Wards of Shahid MadanI Hospital in Khoy City, 2014. Journal of Nursing and Midwifery Urmia University of Medical [Research]. 2016;14(2):100-7.
22
Sayed ME, Jabbour E, Maatouk A, Bachir R, Dagher GA. Discharge Against Medical Advice From the Emergency Department: Results From a Tertiary Care Hospital in Beirut, Lebanon. 2016; 95(6): e2788.
23
ORIGINAL_ARTICLE
Association Between Increased Expression Levels of SDF-1 and CXCR4 on the Platelets of Patients With Coronary Artery Disease and Low LVEF
Background: Since coronary artery disease (CAD) is one of the leading causes of death globally, identifying new risk factors can augment risk assessment. This study aimed to investigate the surface expression of stromal cell-derived factor-1 (SDF-1), CXCR4, and CXCR7 on the platelets of CAD patients and to determine whether there is a correlation between their expressions and left ventricular ejection fraction (LVEF).
Methods: Sixty CAD patients and 60 healthy volunteers as normal controls were studied. The mean fluorescence intensity (MFI) of SDF-1 and its receptor expression was evaluated by flow cytometry. Biochemical markers and platelet parameters were investigated with an AutoAnalyzer and a cell counter, respectively.
Results: The platelets of the CAD group expressed SDF-1 and CXCR4 significantly more than those of the control group (MFI=1112±304 vs 943±131; P=0.042 and MFI=23372±6804 vs 20634±3482; P=0.033, respectively). Nevertheless, no significant difference was found in the platelet expression of CXCR7 between the CAD and control groups (MFI=35256±8706 vs 25053±7270; P=0.061). Notably, increased expression levels of SDF-1 and CXCR4 were associated with decreased LVEF (r= −0.388, P=0.003 and r= −0.431, P=0.001).
Conclusions: Our findings demonstrated that the overexpression of SDF-1 and CXCR4 on platelets could be considered a promising candidate indicating that asymptomatic patients with decreased LVEF may be at the risk of CAD. (Iranian Heart Journal 2022; 23(1): 42-53)
http://journal.iha.org.ir/article_142598_d4c325e436e4c8637c10c6f25a3da48f.pdf
2022-01-01
42
53
SDF-1
CXCR4
CXCR7
Coronary artery disease (CAD)
Platelet markers
Mahdieh
Mehrpouri
mahdiyemehrpoori@gmail.com
1
Department of Laboratory Sciences, School of Allied Medical Sciences, Alborz University of Medical Sciences, Karaj, IR Iran.
AUTHOR
Davood
Bashash
david_5980@yahoo.com
2
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad Esmail
Gheydari
drgheydari@gmail.com
3
Department of Cardiology, Taleghani general Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad hossien
Mohammadi
mohamad.mohamadi2@gmail.com
4
HSC Research Center- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ahmad reza
Baghestani
baghestani.ar@gmail.com
5
Physiotherapy Research Center, Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohsen
Hamidpour
mohsenhp@sbmu.ac.ir
6
HSC Research Center- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine. 2006;3(11):e442.
1
Members WG, Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-e151.
2
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399-410.
3
Association AH. Heart Disease and Stroke Statistics 2017 At-a-Glance. on-line at: http://www heart org/idc/groups/ahamahpublic/@ wcm/@ sop/@ smd/documents/downloadable/ucm_491265 pdf. 2017.
4
Hajar R. Risk factors for coronary artery disease: Historical perspectives. Heart views: the official journal of the Gulf Heart Association. 2017;18(3):109.
5
Akhabue E, Thiboutot J, Cheng J-w, Lerakis S, Vittorio TJ, Christodoulidis G, et al. New and emerging risk factors for coronary heart disease. The American journal of the medical sciences. 2014;347(2):151-8.
6
Aukrust Pl, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, et al. Chemokines and cardiovascular risk. Arteriosclerosis, thrombosis, and vascular biology. 2008;28(11):1909-19.
7
Laflamme MA, Murry CE. Heart regeneration. Nature. 2011;473(7347):326.
8
van der Vorst EP, Döring Y, Weber C. MIF and CXCL12 in cardiovascular diseases: functional differences and similarities. Frontiers in immunology. 2015;6:373.
9
Chatterjee M, Gawaz M. Platelet‐derived CXCL 12 (SDF‐1α): basic mechanisms and clinical implications. Journal of Thrombosis and Haemostasis. 2013;11(11):1954-67.
10
Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell–derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110(21):3300-5.
11
Geisler T, Fekecs L, Wurster T, Chiribiri A, Schuster A, Nagel E, et al. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. European journal of radiology. 2012;81(4):e486-e90.
12
Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry. 2005.
13
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical cancer research. 2010:1078-0432. CCR-09-2329.
14
Yamaguchi J-i, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell–derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107(9):1322-8.
15
Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes H-G, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PloS one. 2010;5(2):e9175.
16
Melo RdCC, Ferro KPV, Duarte AdSS, Saad STO. CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells. Stem cell research & therapy. 2018;9(1):34.
17
D'Souza M, Sarkisian L, Saaby L, Poulsen TS, Gerke O, Larsen TB, et al. Diagnosis of unstable angina pectoris has declined markedly with the advent of more sensitive troponin assays. The American journal of medicine. 2015;128(8):852-60.
18
Bax JJ, Baumgartner H, Ceconi C, Dean V, Fagard R, Funck-Brentano C, et al. Third universal definition of myocardial infarction. Journal of the American College of Cardiology. 2012;60(16):1581-98.
19
Rath D, Chatterjee M, Borst O, Müller K, Stellos K, Mack AF, et al. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. European heart journal. 2013;35(6):386-94.
20
Kajstura J, Urbanek K, Rota M, Bearzi C, Hosoda T, Bolli R, et al. Cardiac stem cells and myocardial disease. Journal of molecular and cellular cardiology. 2008;45(4):505-13.
21
Stellos K, Bigalke B, Langer H, Geisler T, Schad A, Kögel A, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. European heart journal. 2008;30(5):584-93.
22
Mehrpouri M, Bashash D, Mohammadi MH, Gheydari ME, Satlsar ES, Hamidpour M. Co-culture of Platelets with Monocytes Induced M2 Macrophage Polarization and Formation of Foam Cells: Shedding Light on the Crucial Role of Platelets in Monocyte Differentiation. Turkish Journal of Hematology. 2019;36(2):97.
23
Derakhshan R, Arababadi MK, Ahmadi Z, Karimabad MN, Salehabadi VA, Abedinzadeh M, et al. Increased circulating levels of SDF-1 (CXCL12) in type 2 diabetic patients are correlated to disease state but are unrelated to polymorphism of the SDF-1β gene in the Iranian population. Inflammation. 2012;35(3):900-4.
24
Li S-L, Lin W, Zhang Y, Zheng Z-C, Liu L-J, Fu H, et al. Stromal Cell-Derived Factor-1α as a Novel Biomarker for Hyperlipidemia. The Tohoku journal of experimental medicine. 2012;228(4):355-63.
25
Ribeiro V, Bosquetti B, Gonçalves SM, Bucharles SGE, Rempel L, Maciel RAP, et al. Uremic serum inhibits in vitro expression of chemokine SDF-1: impact of uremic toxicity on endothelial injury. Jornal Brasileiro de Nefrologia. 2014;36(2):123-31.
26
Chu H, Chen W-L, Huang C-C, Chang H-Y, Kuo H-Y, Gau C-M, et al. Diagnostic performance of mean platelet volume for patients with acute coronary syndrome visiting an emergency department with acute chest pain: the Chinese scenario. Emergency Medicine Journal. 2010:emj. 2010.093096.
27
Ihara A, Kawamoto T, Matsumoto K, Shouno S, Hirahara C, Morimoto T, et al. Relationship between platelet indexes and coronary angiographic findings in patients with ischemic heart disease. Pathophysiology of haemostasis and thrombosis. 2006;35(5):376-9.
28
Islam M, Siddiqui N, Begum M, Bhuiyan A, Rahman M, Ahammed S. Diagnostic Importance of Platelet in Patients with Acute Coronary Syndrome Admitted in Mymensingh Medical College Hospital. Mymensingh medical journal: MMJ. 2017;26(1):61-7.
29
Lippi G, Filippozzi L, Salvagno GL, Montagnana M, Franchini M, Guidi GC, et al. Increased mean platelet volume in patients with acute coronary syndromes. Archives of pathology & laboratory medicine. 2009;133(9):1441-3.
30
Rodrigues B, França HH, Maiello JR, Romanini S, Pasuld F, Nunes E, et al. Mean Platelet Volume (MPV) Analysis In Patients with Coronary Arterial Disease. Am Soc Hematology; 2010.
31
Majumder B, Jain H, Chatterjee S, Das TK. Study of platelet count and platelet volume indices in the spectrum of coronary artery diseases and its clinicopathological correlation. Nigerian Journal of Cardiology. 2018;15(1):63.
32
Freixa X, Chan J, Bonan R, Ibrahim R, Lamarche Y, Demers P, et al. Impact of coronary artery disease on left ventricular ejection fraction recovery following transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions. 2015;85(3):450-8.
33
Squeri A, Gaibazzi N, Reverberi C, Caracciolo MM, Ardissino D, Gherli T. Ejection fraction change and coronary artery disease severity: a vasodilator contrast stress-echocardiography study. Journal of the American Society of Echocardiography. 2012;25(4):454-9.
34
Yun S-H, Sim E-H, Goh R-Y, Park J-I, Han J-Y. Platelet activation: the mechanisms and potential biomarkers. BioMed research international. 2016;2016.
35
ORIGINAL_ARTICLE
N-terminal pro B-type Natriuretic Peptide Levels and Dilated Cardiomyopathy: A Tissue Doppler Echocardiographic Study in Children
Background: The N-terminal segment of the pro-brain natriuretic peptide (NT-proBNP) has emerged as a marker for heart failure. Dilated cardiomyopathy (DCM) as a major cause of congestive heart failure in children leads to a low cardiac output. However, only a few studies have shown the role of tissue Doppler imaging (TDI) in children with DCM. We sought to explore the associations between TDI parameters and NT-proBNP among DCM patients.
Methods: The present cross-sectional study consecutively enrolled 28 children with DCM. All the patients were on medical therapies in a stable condition upon entrance into the study. All the children were examined by 2D transthoracic echocardiography. TDI imaging was taken from lateral and septal mitral valve areas, and myocardial velocity was calculated by TDI. All the children gave blood samples for the measurement of the NT-proBNP level.
Results: Seventeen patients (60.7%) were female, and the patients’ median age was 10 (IQR25%-75%: 1 to 13) years. The NT-proBNP median was 8614 (IQR25%-75%, 2592 to 20909) pg/mL. There were statistically significant linear relationships between the NT-proBNP level and the lateral myocardial performance index (MPI) (ρ=0.416), the septal MPI (ρ=0.740), the septal E/e´ (ρ=0.533), and the lateral E/e´ (ρ=0.448). The strongest correlation coefficients were observed between the NT-proBNP level and the left ventricular ejection fraction (ρ= −0.754; P=0.001) and the septal MPI (ρ=0.740; P=0.001), even after indexing by body surface area.
Conclusions: NT-proBNP levels correlated strongly with the left ventricular function measured by TDI parameters. Noninvasive echocardiographic evaluations can be implemented to assess children with DCM. (Iranian Heart Journal 2022; 23(1): 54-64)
http://journal.iha.org.ir/article_142599_81d87ef5863c4cabc60f30f8f398bdc9.pdf
2022-01-01
54
64
dilated cardiomyopathy
Brain natriuretic peptides
TISSUE DOPPLER IMAGING
echocardiography
Avisa
Tabib
avtabib@yahoo.com
1
Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad
Mahdavi
md.niaki.rhc@gmail.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Maryam
Moradian
moradian_maryam@gmail.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Feisal
Rahimpour
feisalrahimpoor@gmail.com
4
Pediatric Department, Medical Faculty, Mashhad University of Medical Sciences (MUMS), Mashhad, IR Iran.
LEAD_AUTHOR
Yousef
Rezaei
yousefrezaei1986@gmail.com
5
Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002; 44:293-321.
1
Tabib A, Emamzadegan R, Bakhshandeh H, Givtaj N. Prognostic Value of Serum B-Type Natriuretic Peptide in Early Mortality and Morbidity of Children with Congenital Heart Disease after Open Heart Surgery. Journal of Tehran University Heart Center 2009; 4.
2
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
3
Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107-115.
4
Das BB. Plasma B-type natriuretic peptides in children with cardiovascular diseases. Pediatric cardiology 2010; 31:1135-1145.
5
Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatric cardiology 2004; 25:341-346.
6
den Boer SL, Rizopoulos D, du Marchie Sarvaas GJ, Backx AP, Ten Harkel AD, van Iperen GG, Rammeloo LA, Tanke RB, Boersma E, Helbing WA, Dalinghaus M. Usefulness of Serial N-terminal Pro-B-type Natriuretic Peptide Measurements to Predict Cardiac Death in Acute and Chronic Dilated Cardiomyopathy in Children. The American journal of cardiology 2016; 118:1723-1729.
7
Sacca L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail 2009; 2:151-156.
8
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807-1816.
9
Tsirka AE, Trinkaus K, Chen SC, Lipshultz SE, Towbin JA, Colan SD, Exil V, Strauss AW, Canter CE. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. Journal of the American College of Cardiology 2004; 44:391-397.
10
Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002; 110:e76.
11
Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, Mahony L, Pahl E, Hsu DT. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Circ Heart Fail 2010; 3:606-611.
12
Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW, Towbin JA, Dreyer WJ. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006; 114:1063-1069.
13
Kim G, Lee OJ, Kang IS, Song J, Huh J. Clinical implications of serial serum N-terminal prohormone brain natriuretic peptide levels in the prediction of outcome in children with dilated cardiomyopathy. The American journal of cardiology 2013; 112:1455-1460.
14
Naderi N, Heidarali M, Barzegari F, Ghadrdoost B, Amin A, Taghavi S. Hormonal Profile in Patients With Dilated Cardiomyopathy. Res Cardiovasc Med 2015; 4:e27631.
15
Iacob D, Butnariu A, Leucuta DC, Samasca G, Deleanu D, Lupan I. Evaluation of NT-proBNP in children with heart failure younger than 3 years old. Rom J Intern Med 2017; 55:69-74.
16
Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, Lee MM, Park YB, Choi YS, Seo JD, Lee YW. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474-480.
17
Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Effects of first myocardial infarction on left ventricular systolic and diastolic function with the use of mitral annular velocity determined by pulsed wave doppler tissue imaging. J Am Soc Echocardiogr 2000; 13:343-352.
18
Al-Biltagi MA, Abd Rab Elrasoul Tolba O, El Mahdy H, Donia A, Elbanna S. Echocardiographic assessment of left ventricular dyssynchrony in Egyptian children with congestive heart failure due to dilated cardiomyopathy. Cardiol Young 2015; 25:1173-1181.
19
Mohammed A, Mertens L, Friedberg MK. Relations between systolic and diastolic function in children with dilated and hypertrophic cardiomyopathy as assessed by tissue Doppler imaging. J Am Soc Echocardiogr 2009; 22:145-151.
20
Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, Duboc D, Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio AL, Charron P. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016; 37:1850-1858.
21
Tekten T, Onbasili AO, Ceyhan C, Unal S, Discigil B. Value of measuring myocardial performance index by tissue Doppler echocardiography in normal and diseased heart. Japanese heart journal 2003; 44:403-416.
22
Cantinotti M, Giordano R, Scalese M, Murzi B, Assanta N, Spadoni I, Crocetti M, Marotta M, Molinaro S, Kutty S, Iervasi G. Nomograms for mitral inflow Doppler and tissue Doppler velocities in Caucasian children. Journal of cardiology 2016; 68:288-299.
23
Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatric cardiology 2009; 30:3-8.
24
Koura HM, Abdalla NM, Hamed Ibrahim M, Abo Hashish MM, Zaki SM. NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy. Iran J Pediatr 2016; 26:e4485.
25
Kocharian A, Shabanian R, Rahimzadeh M, Kiani A, Hosseini A, Zanjani KS, Heidari-Bateni G, Hosseini-Navid N. N-terminal pro-B-type natriuretic peptide and ventricular dysfunction in children and adolescents. Cardiol Young 2009; 19:580-588.
26
Foster E, Lease KE. New untwist on diastole: what goes around comes back. Circulation 2006; 113:2477-2479.
27
Goto T, Ohte N, Wakami K, Asada K, Fukuta H, Mukai S, Tani T, Kimura G. Usefulness of plasma brain natriuretic peptide measurement and tissue Doppler imaging in identifying isolated left ventricular diastolic dysfunction without heart failure. The American journal of cardiology 2010; 106:87-91.
28
Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 2004; 148:895-902.
29
Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, Garcia A, Chiu A, De Maria A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141:367-374.
30
Park HS, Naik SD, Aronow WS, Visintainer PF, Das M, McClung JA, Belkin RN. Differences of lateral and septal mitral annulus velocity by tissue Doppler imaging in the evaluation of left ventricular diastolic function. The American journal of cardiology 2006; 98:970-972.
31
Baggish AL, van Kimmenade RR, Januzzi JL, Jr. Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. The American journal of cardiology 2008; 101:49-55.
32
Kantor PF, Rusconi P, Lipshultz S, Mital S, Wilkinson JD, Burch M. Current applications and Future Needs for Biomarkers in Pediatric Cardiomyopathy and Heart Failure: Summary From The Second International Conference On Pediatric Cardiomyopathy. Progress in pediatric cardiology 2011; 32:11-14.
33
ORIGINAL_ARTICLE
Importance of the Neutrophil-to-Lymphocyte Ratio and the Platelet-to-Lymphocyte Ratio in Patients With Venous Thromboembolism
Background: Acute pulmonary thromboembolism (PTE) is the most common manifestation of venous thromboembolism (VTE). Due to the physiological response of circulating leukocytes to stress, circulation neutrophils increase and lymphocytes decrease. Therefore, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) can be important measures to assess the severity of systemic inflammation. We sought to study NLR and PLR and their relationships with the severity of VTE and mortality.
Methods: The study enrolled 331 patients with VTE from 2014 through 2018. Based on the complete blood count obtained from the peripheral blood samples of the patients on admission, NLR and PLR were calculated. The incidence of VTE with or without PTE, as well as its severity, was determined based on computed tomography angiography findings and the patients’ clinical status.
Results: A positive relationship was observed between PTE and NLR (P=0.01). There was a significant relationship between the NLR and PLR values and PTE based on computed tomography angiography findings (NLR: P=0.001, PLR: P=0.012), but no relationship was detected between the ratios and the patients’ PTE severity based on clinical status. A significant relationship was also observed between NLR and the main pulmonary artery and segmental involvement (P=0.009), while no such association was seen with PLR. Additionally, the results revealed a significant relationship between NLR and mortality (P=0.030).
Conclusions: Our results demonstrated a significant relationship between the NLR and PLR values and PTE severity based on computed tomography angiography results and also mortality in patients with PTE. (Iranian Heart Journal 2022; 23(1): 65-73)
http://journal.iha.org.ir/article_142600_72b49b09341b0a3714a98d96548d8717.pdf
2022-01-01
65
73
Neutrophil
Lymphocyte
platelet
Venous Thromboembolism
Mohammad Javad
Alemzadeh-Ansari
mj.aansari@gmail.com
1
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hoseinali
Basiri
h.basiri@gmail.com
2
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohamad Mehdi
Peighambari
m.peyghambari@yahoo.com
3
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Soudeh
Roudbari
soudeh.r@gmail.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Pegah
Salehi
p.salehi345711@gmail.com
5
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Mohammad
Ameni
m.ameni@gmail.com
6
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Masoud
Roudbari
mroudbari@yahoo.co.uk
7
Department of Biostatistics, School of Public Health, Iran University of medical Sciences, Tehran, IR Iran.
AUTHOR
Hamidreza
Pouraliakbar
hamid.pou@yahoo.com
8
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Yasaman
Khalili
yasamakhalili@gmail.com
9
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
ORIGINAL_ARTICLE
Comparison Between 2D Transthoracic Echocardiography, Transesophageal Echocardiography, and Balloon Sizing Methods for Device Size Selection in Pediatric Patients Undergoing Transcatheter Closure of Atrial Septal Defects
Background: Transcatheter closure of atrial septal defects (ASDs) is considered an alternative technique to surgery, and appropriate device size selection is essential to an effective procedure. We aimed to compare 2D transesophageal echocardiography (TEE), transthoracic echocardiography (TTE), and balloon sizing methods for device size selection in pediatric patients undergoing ASD transcatheter closure and to establish an accurate and simple procedure for device size selection.
Methods: This cross-sectional study was performed on pediatric patients for 8 months in Tehran, Iran. Device size was identified by balloon sizing, 2D TEE, and TTE.
Results: This study enrolled 39 children (64.1% female, average age= 7.1±3.1 y) who underwent successful ASD transcatheter closure. The mean defect size by balloon-stretched diameter measurement was significantly greater than the ASD size measured by 2D TEE and TTE. There was a strong, highly significant positive correlation (P<0.001) between the device waist size and different ASD diameters measured by 2D TEE, TTE, and balloon sizing. A good linear association was found between the ASD size measured by device waist size and 2D TEE (device waist size= 0.99×TEE-derived defect size+1.678; P<0.001) as well as TTE (device waist size= 1.01×TTE-derived defect size+1.17; P<0.001), respectively.
Conclusions: In this study, TEE and TTE-derived defect sizes were significantly associated with the device waist size. Additionally, the equations generated herein may provide a reliable and good prediction for appropriate device size. (Iranian Heart Journal 2022; 23(1): 74-84)
http://journal.iha.org.ir/article_142601_7bc72ae0f97912259668e923eaf34962.pdf
2022-01-01
74
84
ASD
TTE
TEE
children
Iran
Ahmad
Vesal
dr.ahmadvesal@yahoo.com
1
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Maryam
Moradian
dr.maryammoradian@yhaoo.com
2
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohsen
Ghasemnezhad
dr.mohsenghasemnejad@yahoo.com
3
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Avisa
Tabib
dr.avisatabib@yahoo.com
4
Heart Valve Disease Research Center, Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Fariba
Rashidi Ghader
dr.faribarashidighader@yahoo.com
5
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Seyyed Mahmoud
Meraji
dr.seyyedmahmoudmeraji@yahoo.com
6
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Farshad
Jafari
dr.farshadjafari@yahoo.com
7
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hamid Reza
Ghaemi
dr.hamidrezaghaemi@yahoo.com
8
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Solmaz
Heidari
dr.solmaz.heidari@gmail.com
9
Department of Pediatrics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran.
AUTHOR
Shahriar
Barouti
shahriar.barouti@gmail.com
10
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Shooka
Mohammadi
shooka.mohammadi@gmail.com
11
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008; 451:943-948.
1
Dolk H, Loane M, Garne E. a European Surveillance of Congenital Anomalies (EUROCAT) Working Group. Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation 2011; 123:841-849.
2
van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. Journal of the American College of Cardiology 2011; 58:2241-2247.
3
Siabani H, Siabani S, Gholizadeh L. Epidemiology of Congenital Heart Defects in Iran: A Systematic Review. Online Journal of Cardiology Research & Reports 2019.
4
Hoffman JI, Kaplan S. The incidence of congenital heart disease. Journal of the American college of cardiology 2002; 39:1890-1900.
5
Chessa M, Carminati M, Butera G, Bini RM, Drago M, Rosti L, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. Journal of the American College of Cardiology 2002; 39:1061-1065.
6
Xuan Tuan H, Duy Kien V, Le Cuong M, Van Son N, Dalla-Pozza R. Trends in the Prevalence of Atrial Septal Defect and Its Associated Factors among Congenital Heart Disease Patients in Vietnam. Journal of Cardiovascular Development and Disease 2020; 7:2.
7
Rudolph A. Congenital diseases of the heart: clinical-physiological considerations. Third Edition. United States: Wiley-Blackwell, 2009.
8
Wang JK, Tsai SK, Wu MH, Lin MT, Lue HC. Short-and intermediate-term results of transcatheter closure of atrial septal defect with the Amplatzer Septal Occluder. American heart journal 2004; 148:511-517.
9
Gupta SK, Sivasankaran S, Bijulal S, Tharakan JM, Harikrishnan S, Ajit KV. Trans-catheter closure of atrial septal defect: balloon sizing or no balloon sizing–single centre experience. Annals of pediatric cardiology 2011; 4:28.
10
Jang JY, Heo R, Cho MS, Bae J, Hong JA, Lee S, Ahn JM, Park DW, Kim DH, Kang DH, Song JK. Efficacy of 3D transoesophageal echocardiography for transcatheter device closure of atrial septal defect without balloon sizing. European Heart Journal-Cardiovascular Imaging 2018; 19:684-689.
11
Zhu W, Cao QL, Rhodes J, Hijazi ZM. Measurement of atrial septal defect size: a comparative study between three-dimensional transesophageal echocardiography and the standard balloon sizing methods. Pediatric cardiology 2000; 21:465-469.
12
Harper RW, Mottram PM, McGaw DJ. Closure of secundum atrial septal defects with the Amplatzer septal occluder device: techniques and problems. Catheterization and cardiovascular interventions 2002; 57:508-524.
13
Harikrishnan S, Narayanan NK, Sivasubramonian S. Sizing balloon-induced tear of the atrial septum. Journal of Invasive Cardiology 2005; 17:546-547.
14
Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. Journal of the American College of Cardiology 2005; 45:1213-1218.
15
Tseng HC, Hsiao PN, Lin YH, Wang JK, Tsai SK. • Transesophageal Echocardiographic Monitoring for Transcatheter Closure of Atrial Septal Defect. Journal of the Formosan Medical Association. 2000; 99:684-688.
16
Carcagnì A, Presbitero P. New echocardiographic diameter for Amplatzer sizing in adult patients with secundum atrial septal defect: preliminary results. Catheterization and cardiovascular interventions 2004; 62:409-414.
17
Chen FL, Hsiung MC, Hsieh KS, Li YC, Chou MC. Real time three-dimensional transthoracic echocardiography for guiding Amplatzer septal occluder device deployment in patients with atrial septal defect. Echocardiography 2006; 23:763-770.
18
Pacileo G, Di Salvo G, Limongelli G, Miele T, Calabrò R. Echocardiography in congenital heart disease: usefulness, limits and new techniques. Journal of cardiovascular medicine. 2007; 8:17-22.
19
Hage FG, Raslan S, Dean P, Nanda NC. Real time three‐dimensional transthoracic echocardiography in congenital heart disease. Echocardiography 2012; 29:220-231.
20
Zanchetta M. On-line intracardiac echocardiography alone for Amplatzer Septal Occluder selection and device deployment in adult patients with atrial septal defect. International journal of cardiology 2004; 95:61-68.
21
Silvestry FE, Cohen MS, Armsby LB, Burkule NJ, Fleishman CE, Hijazi ZM, et al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale: from the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. Journal of the American Society of Echocardiography. 2015; 28:910-958.
22
Esmaeili H, Vahidshahi K, Moradian M, Mortezaeian H. Change of “Left atrium ejection force” after transcatheter “Atrial septal defect” closure using “AMPLATZER,” in pediatric patients. Research in Cardiovascular Medicine 2018; 7:187.
23
Ghaderian M, Merajie M, Mortezaeian H, Aarabi M, Mohammad Y, Mohammadi AS. Efficacy and safety of using amplatzer ductal occluder for transcatheter closure of perimembranous ventricular septal defect in pediatrics. Iranian Journal of Pediatrics 2015; 25.
24
Ghaderian M, Merajie M, Mortezaeian H, Moghadam MY, Mohammadi AS. Mid-term follow-up of the Transcatheter closure of Perimembranous ventricular septal defects in children using the Amplatzer. The Journal of Tehran University Heart Center 2015; 10:182.
25
Mortezaeian H, Zanjani KS, Rad EM. Transcatheter atrial septal defect closure using Occlutech Figulla device: A two-center experience. The Journal of Tehran University Heart Center 2013; 8:197.
26
Levi DS, Moore JW. Embolization and retrieval of the Amplatzer septal occluder. Catheterization and cardiovascular interventions 2004; 61:543-7.
27
Zanchetta M, Onorato E, Rigatelli G, Pedon L, Zennaro M, Carrozza A, Maiolino P. Intracardiac echocardiography-guided transcatheter closure of secundum atrial septal defect: a new efficient device selection method. Journal of the American College of Cardiology 2003; 42:1677-1682.
28
Carlson KM, Justino H, O'Brien RE, Dimas VV, Leonard Jr GT, Pignatelli RH, et al. Transcatheter atrial septal defect closure: modified balloon sizing technique to avoid overstretching the defect and oversizing the Amplatzer septal occluder. Catheterization and cardiovascular interventions 2005; 66:390-396.
29
Amin Z, Danford DA. Balloon sizing is not necessary for closure of secundum atrial septal defects. Journal of the American College of Cardiology 2005; 45:317.
30
Hajizeinali A, Alidoosti M, Sadeghian H, Zoroufian A, Rezvanfard M, Volman MA. A comparison between size of the occluder device and two-dimensional transoesophageal echocardiographic sizing of the ostium secundum atrial septal defect. Cardiovascular journal of Africa 2013; 24:161-164.
31
Sadeghian H, Hajizeinali A, Eslami B, Lotfi-Tokaldany M, Sheikhfathollahi M, Sahebjam M, Hakki E, et al. Measurement of atrial septal defect size: a comparative study between transesophageal echocardiography and balloon occlusive diameter method. The Journal of Tehran Heart Center. 2010; 5:74-77.
32
Helgason H, Johansson M, Söderberg B, Eriksson P. Sizing of atrial septal defects in adults. Cardiology 2005; 104:1-5.
33
Mesihović-Dinarević S, Begić Z, Halimić M, Kadić A, Gojak R. Reliability of transthoracic and transesophageal echocardiography in predicting the size of atrial septal defect. Acta Medica Academica. 2012; 41:145-153.
34
ORIGINAL_ARTICLE
Impact of Drug-Eluting Stent Expansion on Saphenous Vein Graft Percutaneous Intervention
Background: We intended to evaluate the effects of stent expansion in percutaneous coronary intervention (PCI) on saphenous vein graft (SVG) lesions and compare over-expansion and under-expansion between SVG stents in the case of major adverse cardiac events (MACE).
Methods: Totally, 196 SVG lesions were treated with drug-eluting stents. The ratio of the stent diameter to the diameter of the normal part of the SVG (which was without lesions and considered the reference part of the SVG) was measured by quantitative coronary angiography. Subsequently, the patients were divided into 3 groups: Group I (<0.90 expansion: undersized stents), Group II (0.90–1.0 expansion: normal-sized stents), and Group III (>1.0: oversized stents). MACE rates during PCI, hospitalization length, and follow-up findings were compared between the groups. Additionally, the effects of the embolic protection device (EPD) on MACE were assessed.
Results: Oversized stenting was associated with increased cardiac enzymes (P=0.035) during hospitalization but was not associated with more MACE or restenosis on follow-up. Statistical analysis demonstrated nonsignificant more revascularization in the oversized group mainly due to unknown vessel revascularization and non-target vessel revascularization (P=0.167 and P=0.108, respectively). There were no differences in other MACE outcomes. The EPD was used in 25% of the patients. By comparison with the group without the EPD, there was no decrease in MACE components except a higher incidence of heart failure in the EPD group (P=0.03).
Conclusions: Aggressive stent expansion in SVG lesions resulted in higher myocardial injury; and unlike native arteries, there was no improvement in target vessel revascularization rates at follow-up. (Iranian Heart Journal 2022; 23(1): 85-94)
http://journal.iha.org.ir/article_142602_b77d80cf07f2578038fd88fe90239602.pdf
2022-01-01
85
94
Saphenous vein graft
PCI
Stent expansion
Mohammad Javad
Alamzadeh-Ansari
mj.ansaari@gmail.com
1
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ata
Firouzi
atafirouzi@yahoo.com
2
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mousa
Alimohammadi
mousaalimohammadi@gmail.com
3
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ehsan
Khalilipur
ehsankhalilipur@gmail.com
4
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Feridoun
Noohi
fnoohib@yahoo.com
5
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Majid
Maleki
majid33@yahoo.com
6
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad Mehdi
Peighambari
mehdipei@gmail.com
7
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Bahram
Mohebbi
roodbar@yahoo.com
8
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ali
Zadehmehr
arashzahedmehr@yahoo.com
9
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Alireza
Rashidinejad
alirezarashidinejad@gmail.com
10
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Farshad
Shakerian
farshadshakerian@gmail.com
11
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Reza
Kiani
re.kiani@gmail.com
12
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hooman
Bakhshandeh
hooman.bakhshande@gmail.com
13
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Widimsky P, Straka Z, Stros P, Jirasek K, Dvorak J, Votava J, et al. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation. 2004; 110(22):3418-23.
1
Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. Journal of the American College of Cardiology. 2004; 44(11):2149-56.
2
Beijk M, Harskamp R. Treatment of coronary artery bypass graft failure. Artery Bypass: IntechOpen; 2013.
3
Campeau L, Enjalbert M, Lespérance J, Vaislic C, Grondin C, Bourassa M. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation. 1983;68(3 Pt 2):II1-7.
4
McKavanagh P, Yanagawa B, Zawadowski G, Cheema A. Management and prevention of saphenous vein graft failure: a review. Cardiology and therapy. 2017; 6(2):203-23.
5
Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, et al. Treatment of no‐reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheterization and cardiovascular diagnosis. 1996; 39(2):113-8.
6
Baim DS, Carrozza Jr JP. Editorial comment: Understanding the “no‐reflow” problem. Catheterization and cardiovascular diagnosis. 1996; 39(1):7-8.
7
Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. American heart journal. 1995; 130(2):239-43.
8
Lee MS, Park S-J, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, et al. Saphenous vein graft intervention. JACC: Cardiovascular Interventions. 2011; 4(8):831-43.
9
Lefkovits J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, et al. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Circulation. 1995; 92(4):734-40.
10
de Feyter PJ, van Suylen R-J, de Jaegere PP, Topol EJ, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. Journal of the American College of Cardiology. 1993;21(7):1539-49.
11
Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999; 100(24):2400-5.
12
Hong MK, Mehran R, Dangas G, Mintz GS, Lansky A, Kent KM, et al. Are we making progress with percutaneous saphenous vein graft treatment?: A comparison of 1990 to 1994 and 1995 to 1998 results. Journal of the American College of Cardiology. 2001; 38(1):150-4.
13
Nguyen T, Pham L, Cheem TH, Douglas JS, Hermiller J, Grines C. Approach to the patient with prior bypass surgery. Journal of interventional cardiology. 2004;17(5):339-46.
14
Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002; 105(11):1285-90.
15
Grygier M, Araszkiewicz A, Lesiak M, Grajek S. Intracoronary adenosine administered during aortocoronary vein graft interventions may reduce the incidence of no-reflow phenomenon. A pilot randomised trial. Kardiol Pol. 2014; 72(2):126-33.
16
Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. Journal of the American College of Cardiology. 2007; 50(15):1442-9.
17
Hong YJ, Pichard AD, Mintz GS, Kim SW, Lee SY, Kim SY, et al. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. The American journal of cardiology. 2010; 105(2):179-85.
18
Verbin C, White R, Donayre C, Kopchok G. The ideal guidance imaging system for endovascular interventions. The Journal of cardiovascular surgery. 1996; 37(3 Suppl 1):5-9.
19
Elezi S, Kastrati A, Neumann F-J, Hadamitzky M, Dirschinger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation. 1998; 98(18):1875-80.
20
Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. Journal of the American College of Cardiology. 1998; 32(6):1610-8.
21
Hsieh IC, Chien CC, Chang HJ, Chern MS, Hung KC, Lin FC, et al. Acute and long‐term outcomes of stenting in coronary vessel> 3.0 mm, 3.0–2.5 mm, and< 2.5 mm. Catheterization and cardiovascular interventions. 2001; 53(3):314-22.
22
Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, Aymong ED, et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. The American journal of cardiology. 2004; 93(8):963-8.
23
Circulation. 2002;105:1285–1290
24
Xenogiannis I, Tajti P, Hall AB, Alaswad K, Rinfret S, Nicholson W, Karmpaliotis D, Mashayekhi K, Furkalo S, Cavalcante JL, Burke MN. Update on cardiac catheterization in patients with prior coronary artery bypass graft surgery. JACC: Cardiovascular Interventions. 2019 Aug 14.
25
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Journal of the American College of Cardiology. 2018; 72(18):2231-64.
26
Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996; 28:616-26.
27
Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg. 2004; 77:93-101.
28
Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. Journal of the American College of Cardiology. 1995; 26:895-9.
29
Hsieh IC, Chien CC, Chang HJ, Chern MS, Hung KC, Lin FC, et al. Acute and long‐term outcomes of stenting in coronary vessel> 3.0 mm, 3.0–2.5 mm, and< 2.5 mm. Catheterization and cardiovascular interventions. 2001; 53(3):314-22.
30
Coolong A, Baim DS, Kuntz RE, O’Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L. CLINICAL PERSPECTIVE. Circulation. 2008 Feb 12; 117(6):790-7.
31
Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, Aymong ED, et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. The American journal of cardiology. 2004; 93(8):963-8.
32
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Journal of the American College of Cardiology. 2018; 72(18):2231-64.
33
Pepine C, Holmes Jr D. Coronary artery stents. American College of Cardiology. Journal of the American College of Cardiology. 1996; 28(3):782.
34
Keeley EC, Velez CA, O’Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. Journal of the American College of Cardiology. 2001; 38(3):659-65.
35
Iavouvau I, Dangas G, Mintz GS, et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am I Cardiol. 2004; 93:963-968.
36
Topol EJ, Teirstein PS. Bypass Graft Intervention.Textbook of inteventional cardiology, 8th edition.Philadelphia, Elsevier, 2020, 447-460.
37
Paul TK, Bhatheja S, Panchal HB, Zheng S, Banerjee S, Rao SV, et al. Outcomes of saphenous vein graft intervention with and without embolic protection device: a comprehensive review and meta-analysis. Circulation: Cardiovascular Interventions. 2017; 10(12):e005538.
38
Brennan JM, Al-Hejily W, Dai D, Shaw RE, Trilesskaya M, Rao SV, et al. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. Circulation: Cardiovascular Interventions. 2015; 8(3):e001403.
39
Baim DS, Wahr D, George B, et al. Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts. Circulation. 2002; 105:1285–1290
40
Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. The Lancet. 2011 Sep 17; 378(9796):1071-8.
41
Kheiri B, Osman M, Abdalla A, Ahmed S, Bachuwa G, Hassan M. The short- and long-term outcomes of percutaneous intervention with drug-eluting stent vs bare-metal stent in saphenous vein graft disease: An updated meta-analysis of all randomized clinical trials. Clin Cardiol. 2018; 41(5):685‐692. doi:10.1002/clc.22908
42
ORIGINAL_ARTICLE
Clinical Profile of Patients With Ordinary, Submassive, and Massive Pulmonary Thromboembolism in Rajaie Cardiovascular Medical and Research Center
Background: Acute pulmonary thromboembolism (PTE) is a common condition with an increasing incidence that causes severe complications and death. We herein describe the clinical profile of patients with PTE who were referred to a large tertiary university heart hospital.
Methods: In this retrospective cohort study, the demographic, clinical, and admission data of patients with PTE admitted to Rajaie Cardiovascular Medical and Research Center in 2 consecutive years were reviewed and analyzed. Based on echocardiography findings, clinical presentation, and pulmonary computed tomography findings, the patients were divided into massive, submassive, and minor PTE groups. The study variables, as well as in-hospital mortality, were compared between the groups.
Results: The study population consisted of 328 patients with PTE: 210 patients (64.0%) with ordinary PTE, 88 (26.8%) with submassive PTE, and 30 (9.1%) with massive PTE. The patients with massive PTE were significantly younger (P=0.007) and had a higher rate of tachypnea (P=0.002), tachycardia (P=0.013), and hypotension (P<0.001) at presentation. The patients with submassive PTE were more likely to be male and had higher uric acid levels (P=0.002). Chest pain and hypertension were more frequent in the patients with ordinary PTE (P=0.019 and P=0.016, respectively). In pulmonary computed tomography angiography, the involvement of the left and right pulmonary arteries was more frequently observed in the patients with submassive PTE (P=0.013 and P=0.007, respectively). More patients in the massive PTE group received thrombolytic therapy (P<0.001) with a significantly higher mortality rate (P<0.001), a shorter ICU stay (P=0.001), and a shorter hospitalization period (P<0.001).
Conclusions: Patients with massive PTE have a higher risk of mortality and should be considered for more aggressive therapy. (Iranian Heart Journal 2022; 23(1): 95-105)
http://journal.iha.org.ir/article_142603_7666f09aea67dd2b9bbdd1c224efe697.pdf
2022-01-01
95
105
pulmonary thromboembolism
Epidemiology
Massive pulmonary emboli
Treatment outcome
Hasan Allah
Sadeghi
sadeghi194@yahoo.com
1
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mahmood
Sheikh Fathollahi
mamoosh502002@yahoo.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Sarina
Sadeghi
sarina.sadeghi996@yahoo.com
3
Faculty of Medicine, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Akbar
Nikpajouh
dr.nikpajouh@gmail.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Turetz M, Sideris AT, Friedman OA, Triphathi N, Horowitz JM. Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism. Seminars in interventional radiology. 2018; 35(2):92-98.
1
Monreal M, Mahe I, Bura-Riviere A, Prandoni P, Verhamme P, Brenner B, et al. Pulmonary embolism: Epidemiology and registries. Presse medicale (Paris, France : 1983). 2015; 44(12 Pt 2):e377-383.
2
Danwang C, Bigna JJ, Awana AP, Nzalie RN, Robert A. Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis. Journal of thrombosis and thrombolysis.
3
Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circulation research. 2016; 118(9):1340-1347.
4
Thrombosis: a major contributor to global disease burden. Thrombosis research. 2014; 134(5):931-938.
5
Lee GD, Ju S, Kim JY, Kim TH, Yoo JW, Lee SJ, et al. Risk Factor and Mortality in Patients with Pulmonary Embolism Combined with Infectious Disease. Tuberculosis and respiratory diseases. 2020; 83(2):157-166.
6
Petrovic T, Koller T, Stvrtinova V, Payer J. Cancer as a risk factor for residual pulmonary embolism. International angiology : a journal of the International Union of Angiology. 2012; 31(3):283-288.
7
Pishgahi M, Zarei L, Mohaghegh P, Bozorgmehr R. Pulmonary thromboemboli in smokers and nonsmokers; Risk factors and anatomic disturbution of emboli in CT angiographies. International Journal of Cardiovascular Practice. 2019; 4(2):55-58.
8
Toplis E, Mortimore G. The diagnosis and management of pulmonary embolism. British journal of nursing (Mark Allen Publishing). 2020; 29(1):22-26.
9
Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet (London, England). 2012; 379(9828):1835-1846.
10
Gao H, Liu H, Li Y. Value of D-dimer levels for the diagnosis of pulmonary embolism: An analysis of 32 cases with computed tomography pulmonary angiography. Experimental and therapeutic medicine. 2018; 16(2):1554-1560.
11
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). The European respiratory journal. 2019; 54(3).
12
Fishel RS, Merlino JD, Felner JM. Diagnosis of main-stem pulmonary thromboemboli by transesophageal echocardiography. Echocardiography (Mount Kisco, NY). 1994;11(2):189-195.
13
Anderson DR, Barnes DC. Computerized tomographic pulmonary angiography versus ventilation perfusion lung scanning for the diagnosis of pulmonary embolism. Current opinion in pulmonary medicine. 2009; 15(5):425-429.
14
van Es J, Douma RA, Hezemans RE, Penaloza A, Motte S, Erkens PG, et al. Accuracy of X-ray with perfusion scan in young patients with suspected pulmonary embolism. Thrombosis research. 2015; 136(2):221-224.
15
Bui MH, Le QC, Duong DH, Nguyen TS, Tran BG, Duong TD, et al. Economic burden of venous thromboembolism in surgical patients: A propensity score analysis from the national claims database in Vietnam. PloS one. 2020; 15(4):e0231411.
16
Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. Journal of medical economics. 2011; 14(1):65-74.
17
Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism. Current medical research and opinion. 2010; 26(10):2465-2473.
18
Peacock WF, Singer AJ. Reducing the hospital burden associated with the treatment of pulmonary embolism. Journal of thrombosis and haemostasis : JTH. 2019; 17(5):720-736.
19
Siegal DM, Eikelboom JW, Lee SF, Rangarajan S, Bosch J, Zhu J, et al. Variations in Incidence of Venous Thromboembolism in Low-, Middle- and High-Income Countries. Cardiovascular research.
20
Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. 2011; 123(16):1788-1830.
21
Sharma M, Degoricija V, Legac A, Gradiser M, Vucicevic Z. The epidemiology and diagnostic approach to acute pulmonary embolism in the university hospital. Collegium antropologicum. 2009; 33(1):57-63.
22
Barrett NA, Byrne A, Delaney A, Hibbert M, Ramakrishnan N. Management of massive pulmonary embolism: a retrospective single-centre cohort study. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2010; 12(4):242-247.
23
Moretti AM, Tafuri S, Parisi D, Germinario C. Epidemiology of pulmonary embolism in Apulia from analysis of current data. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2010; 73(1):18-24.
24
Casazza F, Becattini C, Bongarzoni A, Cuccia C, Roncon L, Favretto G, et al. Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thrombosis research. 2012; 130(6):847-852.
25
Calwin Davidsingh S, Srinivasan N, Balaji P, Kalaichelvan U, Mullasari AS. Study of clinical profile and management of patients with pulmonary embolism - single center study. Indian heart journal. 2014; 66(2):197-202.
26
Mookadam F, Jiamsripong P, Goel R, Warsame TA, Emani UR, Khandheria BK. Critical appraisal on the utility of echocardiography in the management of acute pulmonary embolism. Cardiology in review. 2010; 18(1):29-37.
27
Casazza F, Bongarzoni A, Forgione C, Cuccia C, Imperadore F, Arrigo G, et al. Echocardiographic evolution of pulmonary artery pressure after acute pulmonary embolism. Results from IPER registry. Thrombosis research. 2014; 134(6):1224-1228.
28
Kausar S, Khan HS, Nazir MTB, Adeel Ur R, Kayani AM. Acute Pulmonary Embolism: Presentation, Diagnosis, Management and Factors Impacting Clinical Outcome in a Tertiary Cardiac Centre in Pakistan. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2019; 29(8):749-752.
29
Hendriks SV, Bavalia R, van Bemmel T, Bistervels IM, Eijsvogel M, Faber LM, et al. Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study. Thrombosis research. 2020; 193:60-65.
30
ORIGINAL_ARTICLE
Comparison of the Economic Burden Between Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention at a One-Year Follow-up
Background: Cardiovascular disease is one of the leading causes of death and disability in the world. There is limited information about the economic burden of this disease in Iran. This study aimed to compare the economic burden between coronary artery bypass grafting surgery (CABG) and percutaneous coronary intervention (PCI) from 2018 through 2019. Methods: The cost of cardiovascular disease was calculated from a sociological perspective based on a top-down approach. The study samples were 379 cardiac patients with venous congestion above 70% who were sampled at Tehran Heart Center by simple random sampling. The cost information was collected in 3 different periods using the hospital information system and interviewing patients. Results: The direct medical cost of CABG was higher than that of PCI (183 907 460 rials vs 122 508 920 rials). The direct nonmedical cost and the indirect cost of CABG were 15 848 570 rials and 79 420 960 rials, respectively, while these costs were 7 951 900 rials and 26 315 170 rials, respectively, for PCI. Conclusions: At 1 year’s postoperative follow-up, CABG had a higher cost than PCI for the patients and, thus, the country’s healthcare system. (Iranian Heart Journal 2022; 23(1): 106-111)
http://journal.iha.org.ir/article_142604_eac280f99c680e76370210c3826fb2f1.pdf
2022-01-01
106
111
Economic burden
Cost
Open-heart surgery
ANGIOPLASTY
CABG
Sara
Emamgholipour
s-emamgholipour@tums.ac.ir
1
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Sajad
Moeini
sajadmoeini@yahoo.com
2
School of Health, Tehran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Cardiovascular Diseases. Available from: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1.
1
IfHMa E. Global Burden of Disease (GBD) study 2016. Available from: http://www.healthdata.org/iran.
2
Taggart PCI or CABG in coronary artery disease? The Lancet. 2009;373(9670):1150-2.
3
Lee H, Lee KS, Sim SB, Jeong HS, Ahn HM, Chee HK. Trends in Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery in Korea. The Korean journal of thoracic and cardiovascular surgery. 2016; 49(Suppl 1):S60.
4
Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. Jama. 2011; 305(17):1769-76.
5
Stuntz M, Palak A. Recent trends in percutaneous coronary intervention volume in the United States. Value in Health. 2016; 19(7):A641.
6
Federation WH. The costs of CVD. Available from: http://www.championadvocates.org/en/champion-advocates-programme/the-costs-of-cvd.
7
Raghfar H, Sargazi N, Mehraban S, Akbarzadeh M, Vaez Mahdavi M, Vahdati Manesh Z. The economic burden of coronary heart disease in Iran: a bottom-up approach in 2014. Journal of Ardabil University of Medical Sciences. 2018; 18(3):341-56.
8
Emamgholipour S, Akbari Sari A, Geravandi S, Mazrae H. Estimation of Out-of-Pocket and Catastrophic Expenditures among Patients with Cardiovascular Diseases in Khuzestan. Payavard Salamat. 2017; 11(3):297-307. eng.
9
Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice M-C, Puskas J, et al. Five-year outcomes after PCI or CABG for left main coronary disease. New England Journal of Medicine. 2019; 381(19):1820-30.
10
Brandão SMG, Rezende PC, Brunner-La Rocca H-P, Ju YT, de Lima ACP, Takiuti ME, et al. Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. Cost Effectiveness and Resource Allocation. 2018; 16(1):55.
11
Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice M-C, et al. Causes of death following PCI versus CABG in complex CAD: 5-year follow-up of SYNTAX. Journal of the American College of Cardiology. 2016; 67(1):42-55.
12
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clinical and molecular hepatology. 2014 Dec;20(4):327-37. PubMed PMID: 25548737. Pubmed Central PMCID: PMC4278062. Epub 2014/12/31. eng.
13
Sarrafzadegan N, Sadeghi M, Oveisgharan S, Iranipour R. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. Archives of Iranian medicine. 2013;16(3):138.
14
Evaluation IfHMa. Global Burden of Disease (GBD) study 2016. Available from: http://ghdx.healthdata.org/gbd-results-tool.
15
Emamgholipour S, Sari AA, Pakdaman M, Geravandi S. Economic Burden of Cardiovascular Disease in the Southwest of Iran. International Cardiovascular Research Journal. 2018; 12(1)
16
Chang H-S, Kim H-J, Nam C-M, Lim S-J, Jang Y-H, Kim S, et al. The socioeconomic burden of coronary heart disease in Korea. Journal of Preventive Medicine and Public Health. 2012; 45(5):291.
17
colleague ZZa. Cost-effectiveness of CABG vs PCI for Treatment of Multivessel Coronary Disease among Unstable Angina Patients---A Secondary Analysis from ASCERT. Circulation. 2014.
18
David J. Cohen RLO, Elizabeth A. Magnuson ADN colleague. Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease. Circulation. 2014.
19
ORIGINAL_ARTICLE
Can Pulmonary Arterial Pressure Exceeding 15 mm Hg Predict Prognosis in Patients With a Single-Ventricle Defect Undergoing the Glenn Procedure?
Background: The primary goal of the Fontan reconstructive surgery is not only to achieve optimal systemic blood flow and simultaneous controlled pulmonary balance but also to prevent the blood from returning to the ventricles. Such measures as the use of systemic-pulmonary shunts can help achieve the desired outcome in this type of surgery. It appears that reducing the resistance of pulmonary arteries and maintaining pulmonary arterial pressure (PAP) could serve as prognostic factors in patients undergoing this surgery. We sought to test the hypothesis that preserved PAP in patients with a single-ventricle defect undergoing the Fontan procedure via the Glenn shunt implantation could confer a better prognosis. Methods: This retrospective cohort study was conducted on 54 consecutive patients with a single-ventricle defect who underwent the Glenn procedure in Rajaie Cardiovascular Medical and Research Center in Tehran in 2019. Based on PAP assessed by angiography, the patients were classified into 2 groups: PAP equal to or less than 15 mm Hg (n=27) and PAP above 15 mm Hg (n=27). Information on the surgical outcome was compared between the 2 groups. Results: No difference was observed between the groups in the rate of cardiac arrhythmia (P=0.192), but the prevalence rates of ascites (7.4% vs 48.1%; P=0.001) and pleural effusion (33.3% vs 85.2%; P=0.001) were higher in the high-PAP group. The mean length of hospital stay (6.00±2.37 d vs 9.48±6.86 d; P=0.16) and the mean length of ICU stay (3.93±1.07 d vs 5.30±2.30 d; P=0.008) were longer in the high-PAP group. Conclusions: High PAP is regarded as a prognostic factor in patients undergoing the Glenn procedure since it places patients at risk for postoperative ascites and pleural effusion and, thus, the need for long-term hospitalization. (Iranian Heart Journal 2022; 23(1): 112-117)
http://journal.iha.org.ir/article_142605_2a3cf5c0c2070ebb6ff1e55dd074718a.pdf
2022-01-01
112
117
Coronavirus disease 2019 (COVID-19)
Deep vein thrombosis (DVT)
Incidence rate
SARS-CoV-2
Reza
Abbaszadeh
rasemani95@yahoo.com
1
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Behrouz
Azari
behrouzazari@yahoo.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
mahmoud
meraji
meraji.mahmoud@yahoo.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Gholamreza
Azari
azarigh@uswr.ac.ir
4
Department of Basic Sciences, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, IR Iran.
AUTHOR
Yasaman
Khalili
khalili3806@yahoo.com
5
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Akbar
Nikpajouh
dr.nikpajouh@gmail.com
6
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
ORIGINAL_ARTICLE
Electrocardiographic and Echocardiographic Findings in Pre-Liver Transplant Pediatric and Young Adult Patients With Wilson’s Disease: A Case-Control Study
Background: Wilson’s cardiac involvement causes cardiomyopathy, arrhythmia, autonomic nervous system dysfunction, and sudden cardiac death. This study aimed to evaluate cardiac dysfunction in pre-liver transplant patients suffering from Wilson’s disease and to classify their risk of arrhythmia and sudden cardiac death. Methods: This case-control study was performed in the Transplant Coordination Center at Namazi Hospital, Shiraz University of Medical Sciences, between 2012 and 2014. The cardiac function was evaluated with 12-lead electrocardiography and echocardiography (M-mode, color Doppler, and tissue Doppler imaging). P-wave dispersion, QT dispersion, and T peak to T end-dispersion were measured in the patient group, and these values were compared with those in the control group. Results: Totally, 23 patients with Wilson’s disease and 47 healthy individuals were included in this study. P-wave dispersion and QT dispersion were significantly increased in the patients with Wilson’s disease (P<0.05). Pulsed Doppler echocardiographic findings showed significantly increased E and A peak velocities of the mitral and tricuspid annuli in the patient group (P<0.05). Tissue Doppler imaging was in favor of a significant increase in systolic and early and late diastolic velocities of the mitral and tricuspid annuli. Conclusions: The prolongation of P-wave dispersion and QT dispersion renders patients with Wilson’s disease susceptible to atrial and ventricular arrhythmias and sudden cardiac death. The evaluation of the cardiac function of such patients should include color Doppler and tissue Doppler imaging to assess diastolic dysfunction as one of the initial cardiac involvements. (Iranian Heart Journal 2022; 23(1): 118-128)
http://journal.iha.org.ir/article_142606_8f285c45d77648235101dcdb1103b5fe.pdf
2022-01-01
118
128
Cardiac evaluation
Wilson’s disease
diastolic dysfunction
echocardiography
Electrocardiography
Hamid
Amoozgar
www.hamidamoozgar@gmail.com
1
Neonatology and Cardiac Research Center, Shiraz University of Medical Science, Shiraz, Iran.
AUTHOR
sahar
Azadi
saharazadi917@gmail.com
2
Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Mozhgan
Zahmatkeshan
zahmatam@sums.ac.ir
3
Gastroenterhepatology Research Center, Shiraz University of Medical Science, Shiraz, Iran.
AUTHOR
Ali Reza
Safarpour
www.safarpourar@gmail.com
4
Gastroenterhepatology Research Center, Shiraz University of Medical Science, Shiraz, Iran.
AUTHOR
Carta M, Mura G, Sorbello O, Farina G, Demelia L. Quality of Life and Psychiatric Symptoms in Wilson's Disease: the Relevance of Bipolar Disorders. Clin Pract Epidemiol Ment Health 2012; 8:102-109.
1
EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671-685.
2
Hedera P. Wilson's disease: A master of disguise. Parkinsonism Relat Disord 2019; 59:140-145.
3
Pfeiffer RF. Wilson's disease. Handb Clin Neurol 2011; 100:681-709.
4
Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol 2015; 14:103-113.
5
Poujois A, Woimant F. Wilson's disease: A 2017 update. Clin Res Hepatol Gastroenterol 2018; 42:512-520.
6
Meenakshi-Sundaram S, Sinha S, Rao M, Prashanth LK, Arunodaya GR, Rao S, et al. Cardiac involvement in Wilson's disease--an electrocardiographic observation. J Assoc Physicians India 2004; 52:294-296.
7
Kuan P. Cardiac Wilson's disease. Chest 1987;91:579-583.
8
Lim CT, Choo KE. Wilson's disease--in a 2 year old child. J Singapore Paediatr Soc 1979; 21:99-102.
9
Ko S, Lee T, Ng S, Lin J, Cheng Y. Unusual liver MR findings of Wilson's disease in an asymptomatic 2-year-old girl. Abdom Imaging 1998; 23:56-59.
10
Nakayama K, Kubota M, Katoh Y, Sawada Y, Saito A, Nishimura K, et al. Early and presymptomatic detection of Wilson's disease at the mandatory 3-year-old medical health care examination in Hokkaido Prefecture with the use of a novel automated urinary ceruloplasmin assay. Mol Genet Metab 2008; 94:363-367.
11
Hermann W, Eggers B, Wagner A. The indication for liver transplant to improve neurological symptoms in a patient with Wilson's disease. J Neurol 2002; 249:1733-1734.
12
Grümayer ER, Weippl G. [Acute hemolysis and liver cirrhosis as leading symptoms of Wilson's disease in childhood]. Klin Padiatr 1983; 195:355-357.
13
Dilaveris PE, Gialafos JE. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001; 6:159-165.
14
Gurok MG, Korkmaz H, Yıldız S, Bakış D, Atmaca M. QT and P-wave dispersion during the manic phase of bipolar disorder. Neuropsychiatr Dis Treat 2019; 15:1805-1811.
15
Milberg P, Reinsch N, Wasmer K, Mönnig G, Stypmann J, Osada N, et al. Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res 2005; 65:397-404.
16
Rodrigues A, Guimarães-Filho FV, Braga JC, Rodrigues CS, Waib P, Fabron-Junior A, et al. Echocardiography in thalassemic patients on blood transfusions and chelation without heart failure. Arq Bras Cardiol 2013; 100:75-81.
17
Nazer H, Ede R, Mowat A, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986; 27:1377-1381.
18
Arat N, Kacar S, Golbasi Z, Akdogan M, Sokmen Y, Kuran S, et al. P wave dispersion is prolonged in patients with Wilson’s disease. World journal of gastroenterology: WJG 2008; 14:1252.
19
Meenakshi-Sundaram S, Sinha S, Rao M, Prashanth L, Arunodaya G, Rao S, et al. Cardiac involvement in Wilson’s disease-an electrocardiographic observation. JAPI 2004; 52.
20
Dilaveris PE, Gialafos JE. P‐wave dispersion: A novel predictor of paroxysmal atrial fibrillation. Annals of Noninvasive Electrocardiology 2001;6:159-165.
21
Çağlı K, Ergün K, Lafçı G, Gedik HS, Ulaş MM. QT and P wave dispersion. Journal of Ankara University Faculty of Medicine 2005; 58.
22
Soliman RA, Battah AA, Hekaal A, Ashraf MM, Wadei A. The Relationship between P Wave Dispersion and Diastolic Dysfunction in Patients with Significant and Insignificant Coronary Artery Disease. J Am Sci 2010; 6:438-445.
23
KHOSROUPANAH S, Nemati M, BAZARGAN LO, Zare N. Effect of CABG on P-wave Dispersion and the Relationship between AF and P-wave Dispersion 2009.
24
DEDEOĞLU E, BAYRAM B, ÖMÜ D, Hanci V. The P-wave dispersion and QTC durations in the patients with acute pancreatitis. Acta Medica 2014; 30:869.
25
Cevik Y, Tanriverdi F, Delice O, Kavalci C, Sezigen S. Reversible increases in QT dispersion and P wave dispersion during carbon monoxide intoxication. Hong Kong Journal of Emergency Medicine 2010; 17:441-450.
26
Castro H. Antzelevitch C. T peak–T end and T peak–T end dispersion as risk factor for Ventricular tachycardia/Ventricular fibrillation in patients with Brugada syndrome. J Am Coll Cardiol 2006; 47:1828-1834.
27
Topilski I, Rogowski O, Rosso R, Justo D, Copperman Y, Glikson M, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. Journal of the American College of Cardiology 2007; 49:320-328.
28
Elkiran O, Karakurt C, Selimoglu A, Karabiber H, Kocak G, Celik SF, et al. Subclinical diastolic dysfunction in children with Wilson’s disease assessed by tissue Doppler echocardiography: a possible early predictor of cardiac involvement. Acta cardiologica 2013; 68:181-187.
29
ORIGINAL_ARTICLE
COVID-19 Prognosis in Patients With/Without a History of ACEI/ARB Consumption
Background: Hypertension is a critical risk factor in increasing the mortality rate of COVID-19 inpatients. This association can be confounded by a history of consuming some angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs).Objective: This study aimed to assess the COVID-19 prognosis in patients with/without a history of taking ACEIs and ARBs. Methods: This single-center, prospective, observational study was performed on 345 patients with COVID-19 hospitalized in Baqiyatallah Hospital. The patients were categorized into 2 groups: with a history of ACEI/ARB consumption (the case group, n=115) and without such a history (the control group, n=230). Results: After the exclusion of some patients, the COVID-19 prognosis of 294 patients (ncontrol =184, ncase=110, 53% female) at a mean age of 64±9.7 years was evaluated. Unequal variables were adjusted between the case and control groups, and the results showed no significant differences in oxygen saturation, the computed tomography scan score, the erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase, D-dimer, the white blood cell count, lymphocytes, hemoglobin, platelets, and mortality between the 2 groups. However, a significant difference in the average length of hospital stay was found between the control (6.55±0.56 d) and case (8.53±0.55 d) groups (P=0.013). Conclusions: The dosage adjustments and changes of ACEIs and ARBs are not recommended due to increased referrals to health centers involved with the COVID-19 risk. The prognosis, safety, and efficacy of ACEI/ARB consumption should be assessed further in larger studies on middle-aged to old patients with COVID-19. (Iranian Heart Journal 2022; 23(1): 129-139)
http://journal.iha.org.ir/article_142607_c5563b98ca2d2c96e0d5988652af8507.pdf
2022-01-01
129
139
ACE inhibitors
Angiotensin II receptor blockers
Antihypertensive drugs
COVID-19
Hypertension
Mohsen
Sadeghi Ghahrodi
sadeghimg@yahoo.com
1
Department of Cardiology, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Seyed Vahid
Mousavi
shdvmoo@yahoo.com
2
Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Yahya
Dadjou
ydadjou@yahoo.com
3
Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Leila
Khedmat
drlkhedmat@gmail.com
4
Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mansour
Abdollah Zadeh Arpanahi
mansourabdollah55@gmail.com
5
Department of Radiology and Health Research Center Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ramezan
Jafari
rezajafari201089@gmail.com
6
Department of Radiology and Health Research Center Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Houshyar
Maghsoudi
hooshirad@yahoo.com
7
Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad
Gholami Fesharaki
gholami4547@gmail.com
8
Biostatistics Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.
AUTHOR
Atieh
Asadollah
atieh_asadollah@yahoo.com
9
Faculty of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, IR Iran.
AUTHOR
Amirhosein
Ghazale
a.h.ghazale@gmail.com
10
Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Rajan R, Al Jarallah M, Dashti R. Cardiovascular complications of novel Wuhan Coronavirus COVID ndash: A 2020 update. J Cardiol Curr Res. 2020;13(13), 28. doi: 10.15406/jccr.2020.13.00468
1
Mirzadeh M, Khedmat L. Pregnant women in the exposure to COVID-19 infection outbreak: the unseen risk factors and preventive healthcare patterns. J Matern-Fetal Neonatal Med. 2020; doi: 10.1080/14767058.2020.1749257.
2
Khedmat L. New coronavirus (2019-nCoV): An insight toward preventive actions and natural medicine. Int J Travel Med Glob Health. 2020;8(1):44-5. doi: 10.34172/ijtmgh.2020.07.
3
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5.
4
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
5
Amiri P, Vahedi-Notash G, Naseri P, Khalili D, Nazari SS, Mehrabi Y, et al. National trends of pre-hypertension and hypertension among Iranian adolescents across urban and rural areas (2007–2011). Biol Sex Differ. 2019;10(1):15. doi: 10.1186/s13293-019-0230-1.
6
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; doi:10.1016/S0140-6736(20)30566-3.
7
Kloor D, Osswald H. S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. Trends Pharmacol Sci. 2004;25(6):294-7. doi: 10.1016/j.tips.2004.04.004.
8
Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pediatr. 2020;8:206. doi: 10.3389/fped.2020.00206.
9
Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?. JAMA. 2020; 323(18):1769-70. doi:10.1001/jama.2020.4812
10
Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Chin J Tuberc Respir Dis. 2020;43:E014. doi:10.3760/cma.j.issn.1001-0939.2020.0014
11
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Rev Cardiol. 2020;17(5):259-60. doi: 10.1038/s41569-020-0360-5
12
Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(1):45-51. doi: 10.1042/BJ20040634
13
American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Accessed March 20, 2020.https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp
14
European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. Accessed March 20,2020.https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
15
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res. 2020;7(1):article no.11. doi: 10.1186/s40779-020-00240-0.
16
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4.
17
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020:200370. doi: 10.1148/radiol.2020200370.
18
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Res. 2020; 126:1671–81. doi: 10.1161/CIRCRESAHA.120.317134
19
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020; 382:2441-8. doi: 10.1056/NEJMoa2008975.
20
Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. Clin Exp Hypertens. 2020; 42(7):656-660.doi:10.1080/10641963.2020.1764018
21
Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr: Clin Res Rev. 2020; 14(4):283-7. doi: 10.1016/j.dsx.2020.03.016
22
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ.Res. 2020; 126:1671-81. doi: 10.1161/CIRCRESAHA.120.317134
23
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microb Infect. 2020;9(1):757-60. doi: 10.1080/22221751.2020.1746200
24
Gage JR, Fonarow G, Hamilton M, Widawski M, Martínez-Maza O, Vredevoe DL, et al. Beta Blocker and angiotensin-converting enzyme Inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation.2004;11(3):173-180. doi: 10.1159/000076766
25
Andersen LB, Przybyl L, Haase N, von Versen‐Höynck F, Qadri F, Jørgensen JS, et al. Vitamin D depletion aggravates hypertension and target‐organ damage. J Am Heart Assoc. 2015; 4(2):e001417. doi: 10.1161/JAHA.114.001417.
26
Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am JRespir CritCare Med. 2020;201(11):1380-8.doi:10.1164/rccm.202002-0445
27
ORIGINAL_ARTICLE
Relationship Between Demographic Characteristics, Clinical Parameters, and Extubation Time in Post-Cardiac Surgery Patients
Background: Understanding factors influencing extubation in cardiac surgery patients is essential. This study aimed to determine the relationship between demographic characteristics, medical and clinical variables, and the extubation time in patients undergoing cardiac surgery in a cardiovascular center.
Methods: This causal-comparative study was conducted on 210 adult patients who underwent cardiac surgery in 2018 in Tehran. The study samples were selected via the convenience sampling method. The data collection tool was a researcher-made observation checklist that featured 4 sections on the patients’ demographic characteristics, clinical variables during surgery, clinical conditions in the ICU, and high-risk factors related to the disease. The subjects were categorized into 2 study groups of more than 6 hours of mechanical ventilation and equal to or less than 6 hours of mechanical ventilation based on their mechanical ventilation time. Via the multivariate analysis test, the factors affecting endotracheal tube extubation were determined. IBM SPSS Statistics software, version 21, was used for statistical analysis.
Results: The study population consisted of 210 post-cardiac surgery patients, 142 men and 68 women, at a median age of 55 years. The findings indicated that age, sedation, and the duration of pulmonary circulation had a significant influence on the extubation time in post-cardiac surgery patients.
Conclusions: In our sample of post-cardiac surgery patients, age, sedation, and the duration of pulmonary circulation impacted the process of extubation. The implementation of a precise discontinuation program from mechanical ventilation by considering these factors is recommended to prevent long-term mechanical ventilation and shorten the ICU length of stay. (Iranian Heart Journal 2022; 23(1): 140-148)
http://journal.iha.org.ir/article_142608_30a7c380b64e6ea26af79d8256326539.pdf
2022-01-01
140
148
Extubation of the endotracheal tube
Cardiac Surgery
intensive care
Mechanical Ventilation
Nooredin
Mohammadi
nooredin.mohammadi@yahoo.com
1
Nursing Care Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Elham
Shahsavari
elhamshahsavari93@gmail.com
2
Nursing and Midwifery Faculty, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Rasoul
Azarfarin
razarfarin@yahoo.com
3
Echocardiography research center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hooman
Bakhshandeh Abkenar
hooman.bakhshande@gmail.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
AMULA, V., VENER, D. F., PRIBBLE, C. G., RIEGGER, L., WILSON, E. C., SHEKERDEMIAN, L. S., OU, Z., PRESSON, A. P., WITTE, M. K. & NICOLSON, S. C. 2019. Changes in Anesthetic and Postoperative Sedation–Analgesia Practice Associated With Early Extubation Following Infant Cardiac Surgery: Experience From the Pediatric Heart Network Collaborative Learning Study. Pediatric Critical Care Medicine, 20, 931-939.
1
BAINBRIDGE, D. & CHENG, D. C. Early extubation and fast-track management of off-pump cardiac patients in the intensive care unit. Seminars in cardiothoracic and vascular anesthesia, 2015. SAGE Publications Sage CA: Los Angeles, CA, 163-168.
2
BANSAL, S., THAI, H., HSU, C., SAI-SUDHAKAR, C., GOLDMAN, S. & RHENMAN, B. 2013. Fast track extubation post coronary artery bypass graft: a retrospective review of predictors of clinical outcomes. World Journal of Cardiovascular Surgery, 3, 81-86.
3
BARKHORDARI, K., YAGHOOTI, S., NIKKHAH, S., AEIN, A., JALALI, A. & SHAFIEE, A. 2016. Clinical outcome of tracheal extubatedcardiac surgery patients who did not meet protocol driven laboratory criteria for extubation. Tehran University Medical Journal TUMS Publications, 74, 657-663.
4
BASKAR KARTHEKEYAN, R., SYAMA SUNDAR, A., SULAIMAN, S., RAVULAPALLI, H., VAKAMUDI, M. & THANGAVELU, P. 2010. Early Extubation in Ventricular Septal Defect. Journal of Clinical & Experimental Cardiology, 1.
5
BRIMS, F. J., DAVIES, M. G., ELIA, A. & GRIFFITHS, M. J. 2015. The effects of pleural fluid drainage on respiratory function in mechanically ventilated patients after cardiac surgery. BMJ open respiratory research, 2, e000080.
6
CRAWFORD, T. C., MAGRUDER, J. T., GRIMM, J. C., SCIORTINO, C., CONTE, J. V., KIM, B. S., HIGGINS, R. S., CAMERON, D. E., SUSSMAN, M. & WHITMAN, G. J. Early extubation: a proposed new metric. Seminars in thoracic and cardiovascular surgery, 2016. Elsevier, 290-299.
7
FAGHANI, H., MOSAVINASAB, N., GHOLIPOUR BARADARI, A., MOOSAZADEH, M., KHERADMAND, M. & ESMAEILI, R. 2017. Duration of Intubation after Coronary Artery Bypass Graft Surgery and Its Related Factors. Journal of Mazandaran University of Medical Sciences, 26, 68-79.
8
FLYNN, B. C., HE, J., RICHEY, M., WIRTZ, K. & DAON, E. 2019. Early extubation without increased adverse events in high-risk cardiac surgical patients. The Annals of thoracic surgery, 107, 453-459.
9
GUMUS, F., POLAT, A., YEKTAS, A., TOTOZ, T., BAGCI, M., ERENTUG, V. & ALAGOL, A. 2015. Prolonged mechanical ventilation after CABG: risk factor analysis. Journal of cardiothoracic and vascular anesthesia, 29, 52-58.
10
JAFROUDI, S., MEHDIZADEH ATTAR, M., FARMANBAR, R., KAZEM NEJAD LEILI, E. & PARYAD, E. 2014. Predictors' issues of intubation time after coronary artery bypass graft surgery. Journal of Holistic Nursing And Midwifery, 24, 20-29.
11
MADDALI, M. M., KURIAN, & FAHR, J. 2006. Extubation time, hemodynamic stability, and postoperative pain control in patients undergoing coronary artery bypass surgery: An evaluation of fentanyl, remifentanil, and nonsteroidal antiinflammatory drugs with propofol for perioperative and postoperative management. Journal of clinical anesthesia, 18, 605-610.
12
MARDA, M., PANDIA, M. P., RATH, G. P., KALE, S. S. & DASH, H. 2016. A comparative study of early and late extubation following transoral odontoidectomy and posterior fixation. Journal of anaesthesiology, clinical pharmacology, 32, 33.
13
MARTINOS, C., DALIAKOPOULOS, S., TSAKALAKIS, C., GEORGIOU, M. & MORAITIS, S. 2017. The Use of a Fast-Track Protocol for Perioperative Management of Cardiac Surgery Patients. J Anesth Crit Care Open Access, 8, 00301.
14
MIRINEZHAD, S. M., JOUDATI, A. R., SAFAEI, N., AZAR FARIN, R. & BILEHJANI, I. 2005. Early Extubation Following Coronary Artery Bypass Graft Surgery Protocol Versus Midazolam. Medical Journal of Tabriz University Of Medical Sciences, 27, 77-81.
15
MUKERJI, A., RAZAK, A., AGGARWAL, A., JACOBI, E., MUSA, M., ALWAHAB, Z., BAIER, J., NARVEY, M. & SHAH, P. S. 2020. Early versus delayed extubation in extremely preterm neonates: a retrospective cohort study. Journal of Perinatology, 40, 118-123.
16
MYLES, P. S., BUCKLAND, M. R., WEEKS, A. M., BUJOR, M. A., MCRAE, R., LANGLEY, M., MOLONEY, J. T., HUNT, J. O. & DAVIS, B. B. 1997. Hemodynamic effects, myocardial ischemia, and timing of tracheal extubation with propofol-based anesthesia for cardiac surgery. Anesthesia & Analgesia, 84, 12-19.
17
NGUYEN, J. & NACPIL, N. 2018. Effectiveness of dexmedetomidine versus propofol on extubation times, length of stay and mortality rates in adult cardiac surgery patients: a systematic review and meta-analysis. JBI database of systematic reviews and implementation reports, 16, 1220-1239.
18
RAMONCITO, D. A., BROOKE, B. S., HANSON, K. T., GOODNEY, P. P., GENOVESE, E. A., BARIL, D. T., GLOVICZKI, P. & DEMARTINO, R. R. 2017. Early extubation is associated with reduced length of stay and improved outcomes after elective aortic surgery in the Vascular Quality Initiative. Journal of vascular surgery, 66, 79-94. e14.
19
REZAIANZADEH, A., MAGHSOUDI, B., TABATABAEE, H., KESHAVARZI, S., BAGHERI, Z., SAJEDIANFARD, J., GERAMI, H. & RASOULI, J. 2015. RFactors associated with extubation time in coronary artery bypass grafting patients. PeerJ e, 3.
20
SAFAVI, M., M., M. & SADREDDINI, M. 2005. The effect of preoperative training and information on mechanical ventilation and device isolation in patients undergoing CABG in selected hospitals of Tabriz in 2004. Pajoohande, 10, 321-327.
21
SATO, M., SUENAGA, E., KOGA, S., MATSUYAMA, S., KAWASAKI, H. & MAKI, F. 2009. Early tracheal extubation after on-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg, 15, 239-42.
22
SAVARI, S., MOTEDAYEN, Z. & EBADI, A. 2013. Early Extubation in Cardiac Surgery. Journal of Medical Education Development Department, Faculty of Nursing, Baqiyatallah University of Medical Sciences, 14, 15-22.
23
TIERNEY, C. C., OERMANN, M. H., MOLLOY, M. A., BRIEN, L. & NEISLER, C. 2019. Implementing a Weaning Protocol for Cardiac Surgery Patients Using Simulation: A Quality Improvement Project. Dimensions of Critical Care Nursing, 38, 248-255.
24
WILLIAMS, A. & MURPHY, L. S. 2016. Establishing the Content Validity of an Early Extubation Protocol: A Quality Improvement Project for Improving Early Extubation of Coronary Artery Bypass Graft Patients. Journal of Doctoral Nursing Practice, 9, 236-248.
25
WILLIAMSON, C., FITTON, T., SMAROFF, G., TEAGUE, P., SHAFF, D. & CURRAN, J. 2017. Early extubation protocol following valve and coronary artery bypass surgery. Clin Surg. 2017; 2, 1424.
26
ZHOU, Y., JIN, X., KANG, Y., LIANG, G., LIU, T. & DENG, N. 2014. Midazolam and propofol used alone or sequentially for long-term sedation in critically ill, mechanically ventilated patients: a prospective, randomized study. Critical Care, 18, R122.
27
ORIGINAL_ARTICLE
Intravenous Vitamin C to Prevent Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
Background: This retrospective cohort study aimed to evaluate the effects of the intravenous administration of vitamin C before and after exposure to the contrast medium for the prophylaxis of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography. Methods: Data on 210 patients with chronic kidney disease (CKD) (defined as an estimated glomerular filtration rate ≤60 mL/min/1.73m2) were obtained through medical chart reviews and electronic data in 3 different groups: 1) no vitamin C administered, 2) vitamin C administered 30 minutes before angiography, and 3) vitamin C administered 30 minutes after angiography. Each group consisted of 70 patients, and vitamin C was administered intravenously. CIN incidence in all the groups was defined as an increase of 0.5 mg/dL or 25% in serum creatinine levels. Results: Overall, CIN incidence was significantly lower in patients who received intravenous vitamin C before (P≤0.05) and after (P≤0.05) angiography than in patients with no prophylaxis. The post-angiography administration of vitamin C was very effective in diminishing creatinine rise and preventing CIN. CIN occurred in 7.1% of the patients in the pre-administered and post-administered groups. Conclusions: The intravenous administration of vitamin C before and after angiography could effectively decrease CIN incidence in patients undergoing percutaneous coronary intervention. The post-angiography administration of vitamin C is more effective to decrease serum creatinine levels. (Iranian Heart Journal 2022; 23(1): 149-159)
http://journal.iha.org.ir/article_142609_4d91b558b54083471948ea7f0da157cf.pdf
2022-01-01
149
159
Contrast-induced nephropathy
Chronic kidney disease
Coronary Angiography
Vitamin C
Antioxidant
Farzaneh
Futuhi
ff.1975@yahoo.com
1
Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mahshid
Malakootian
mahshid.malakootian@gmail.com
2
Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Majid
Maleki
majid3@yahoo.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad Mehdi
Peighambari
mehdipei@gmail.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Maryam
Hosseini Moghadam
m.hosseinimoghadaam@gmail.com
5
Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad Javad
Hosseini
6
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Shabnam
Boudagh
shabnam.md82@yahoo.com
7
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Maedeh
Arabian
arabian@rhc.ac.ir
8
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Brown JR, Thompson CA. Contrast-induced acute kidney injury: the at-risk patient and protective measures. Curr Cardiol Rep. 2010; 12(5):440-5.
1
Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004; 44(9):1763-71.
2
Hong WY, Kabach M, Feldman G, Jovin IS. Intravenous fluids for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography and cardiac catheterization. Expert Rev Cardiovasc Ther. 2020; 18(1):33-9.
3
Morcos R, Kucharik M, Bansal P, Al Taii H, Manam R, Casale J, et al. Contrast-Induced Acute Kidney Injury: Review and Practical Update. Clin Med Insights Cardiol. 2019;13:1179546819878680.
4
Khajali F, Khajali Z. L-carnitine supplementation decreases lipid peroxidation and improves cardiopulmonary function in broiler chickens reared at high altitude. Acta Vet Hung. 2014;62(4):489-99.
5
Firouzi A, Eshraghi A, Shakerian F, Sanati HR, Salehi N, Zahedmehr A, et al. Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients. Int Urol Nephrol. 2012;44(4):1145-9.
6
Laroussi L, Triki M, Ibn Elhaj Z, Ben Halima A, Boukhris M, Ben Amara W, et al. [Vitamin C+sodium bicarbonate versus sodium bicarbonate alone in preventing contrast-induced nephropathy]. Ann Cardiol Angeiol (Paris). 2017;66(4):190-6.
7
Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;62(23):2167-75.
8
Pisani A, Riccio E, Andreucci M, Faga T, Ashour M, Di Nuzzi A, et al. Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. Biomed Res Int. 2013;2013:868321.
9
Ali-Hasan-Al-Saegh S, Mirhosseini SJ, Ghodratipour Z, Sarafan-Chaharsoughi Z, Dehghan AM, Rahimizadeh E, et al. Protective effects of anti-oxidant supplementations on contrast-induced nephropathy after coronary angiography: an updated and comprehensive meta-analysis and systematic review. Kardiol Pol. 2016;74(7):610-26.
10
Azzalini L, Laricchia A, Regazzoli D, Mitomo S, Hachinohe D, Bellini B, et al. Ultra-Low Contrast Percutaneous Coronary Intervention to Minimize the Risk for Contrast-Induced Acute Kidney Injury in Patients With Severe Chronic Kidney Disease. J Invasive Cardiol. 2019.
11
Atanda AC, Olafiranye O. Contrast-induced acute kidney injury in interventional cardiology: Emerging evidence and unifying mechanisms of protection by remote ischemic conditioning. Cardiovasc Revasc Med. 2017;18(7):549-53.
12
Wybraniec MT, Bozentowicz-Wikarek M, Chudek J, Mizia-Stec K. Pre-procedural renal resistive index accurately predicts contrast-induced acute kidney injury in patients with preserved renal function submitted to coronary angiography. Int J Cardiovasc Imaging. 2017;33(5):595-604.
13
Duan C, Cao Y, Liu Y, Zhou L, Ping K, Tan MT, et al. A New Preprocedure Risk Score for Predicting Contrast-Induced Acute Kidney Injury. Can J Cardiol. 2017;33(6):714-23.
14
Kang X, Hu DY, Li CB, Ai ZS, Peng A. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. Ren Fail. 2015;37(10):297-303.
15
Li Y, Liu Y, Shi D, Yang L, Liang J, Zhou Y. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention. Angiology. 2016;67(2):139-45.
16
Stolker JM, McCullough PA, Rao S, Inzucchi SE, Spertus JA, Maddox TM, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol. 2010;55(14):1433-40.
17
Heunisch F, Chaykovska L, von Einem G, Alter M, Dschietzig T, Kretschmer A, et al. ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography. Medicine (Baltimore). 2017;96(6):e6065.
18
Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, et al. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. Diabetes Res Clin Pract. 2014;106(3):458-64.
19
Yang JQ, Ran P, Chen JY, He YT, Li LW, Tan N, et al. Development of contrast-induced acute kidney injury after elective contrast media exposure in patients with type 2 diabetes mellitus: effect of albuminuria. PLoS One. 2014;9(9):e106454.
20
Feng Y, Huang X, Li L, Chen Z. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis. Nephrology (Carlton). 2018;23(6):530-8.
21
Sharp AJ, Patel N, Reeves BC, Angelini GD, Fiorentino F. Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: a systematic review and meta-analysis of randomised controlled trials. Open Heart. 2019;6(1):e000864.
22
Miyazawa T, Matsumoto A. Determination of cellular vitamin C dynamics by HPLC-DAD. 2019.
23
Subramaniam RM, Wilson RF, Turban S, Suarez-Cuervo C, Zhang A, Sherrod C, et al. AHRQ Comparative Effectiveness Reviews. Contrast-Induced Nephropathy: Comparative Effectiveness of Preventive Measures. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.
24
Navarese EP, Gurbel PA, Andreotti F, Kolodziejczak MM, Palmer SC, Dias S, et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One. 2017;12(2):e0168726.
25
Palli E, Makris D, Papanikolaou J, Garoufalis G, Tsilioni I, Zygoulis P, et al. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study. Crit Care. 2017;21(1):269.
26
Komiyama K, Ashikaga T, Inagaki D, Miyabe T, Arai M, Yoshida K, et al. Sodium Bicarbonate-Ascorbic Acid Combination for Prevention of Contrast-Induced Nephropathy in Chronic Kidney Disease Patients Undergoing Catheterization. Circ J. 2017;81(2):235-40.
27
Liu LY, Liu Y, Wu MY, Sun YY, Ma FZ. Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis. Drug Des Devel Ther. 2018;12:437-44.
28
Hossain MA, Costanzo E, Cosentino J, Patel C, Qaisar H, Singh V, et al. Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl. 2018; 29(1):1-9.
29
Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC, Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990; 258(1 Pt 2):F115-20.
30
Vlachopanos G, Schizas D, Hasemaki N, Georgalis A. Pathophysiology of Contrast-Induced Acute Kidney Injury (CIAKI). Curr Pharm Des. 2019;25(44):4642-7.
31
Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007-15.
32
Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004;44(4):327-37.
33
Ward DB, Valentovic MA. Contrast Induced Acute Kidney Injury and Direct Cytotoxicity of Iodinated Radiocontrast Media on Renal Proximal Tubule Cells. J Pharmacol Exp Ther. 2019;370(2):160-71.
34
ORIGINAL_ARTICLE
Comparison of Vitamin D Status Between Infants With Dilated Cardiomyopathy and Infants With Other Congenital Heart Diseases
Background: Vitamin D plays an essential role in calcium homeostasis and cardiac muscle function, hence the significance of the screening, diagnosing, preventing, and treating of vitamin D deficiency (VDD). In children susceptible to VDD, cardiomyopathy is a likely occurrence. We sought to compare vitamin D status between children with dilated cardiomyopathy (DCM) and children with other congenital heart diseases.
Methods: This observational case-control study, conducted from 2018 through 2019 in Rajaie Cardiovascular Medical and Research Center, compared vitamin D status between a case group, consisting of 33 infants with DCM, and a control group, composed of 35 infants with other congenital heart diseases. The serum levels of iron, magnesium, calcium, albumin, parathyroid hormone, and 25(OH)D3 were measured in all the children.
Results: The study population consisted of 68 infants (31 males and 37 females) at a mean age of 64.96±51 days. The DCM group presented with a significantly higher incidence of VDD (27.3%) than the control group (8.6%). Multivariable-adjusted analysis for DCM based on the tertiles of vitamin D levels revealed an odds ratio of 0.25 (95% CI, 0.06 to 1.01) for tertile 3 (>24 nmol/L) compared with an odds ratio of 0.89 (95% CI, 0.24 to 3.30) for tertile 2 (16–24 nmol/L) and tertile 1 (<16 nmol/L) designated as the reference (P=0.05), indicating near statistical significance.
Conclusions: In assessing a child with newly diagnosed DCM or other congenital heart diseases, VDD and electrolyte imbalances should be promptly screened to avert the precipitating decompensation of the cardiovascular function. (Iranian Heart Journal 2022; 23(1): 160-171)
http://journal.iha.org.ir/article_142610_ab833c2bfac8f64334c04da154efcffd.pdf
2022-01-01
160
171
dilated cardiomyopathy
Infant
Vitamin D
Vitamin D deficiency
Maryam
Aryafar
aryafarmaryam@yahoo.com
1
Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Hamed
Kord Varkaneh
hamedkord39@yahoo.com
2
Student Research Committee, Department of Clinical Nutrition and Dietetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
vaani
kathirgamathamby
vaani.kathirgamathamby@yahoo.com
3
Department of Medicine and Life Sciences, Kings College London, University of London, Strand, London, WC2R 2LS.
AUTHOR
zahra
Fotovati
z.fotovati9@gmail.com
4
Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Mohammad
Mahdavi
md_niaki@yahoo.com
5
Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
shiva
khaleghparast
sh_khaleghparast@yahoo.com
6
Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Richardson, P., et al., Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation, 1996. 93(5): p. 841-2.
1
Kirk, R., et al., Outcome of pediatric patients with dilated cardiomyopathy listed for transplant: a multi-institutional study. The Journal of Heart and Lung Transplantation, 2009. 28(12): p. 1322-1328.
2
Towbin, J.A., et al., Incidence, causes, and outcomes of dilated cardiomyopathy in children. Jama, 2006. 296(15): p. 1867-76.
3
Tsirka, A.E., et al., Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol, 2004. 44(2): p. 391-7.
4
Lipshultz, S.E., et al., The Incidence of Pediatric Cardiomyopathy in Two Regions of the United States. New England Journal of Medicine, 2003. 348(17): p. 1647-1655.
5
Nugent, A.W., et al., The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med, 2003. 348(17): p. 1639-46.
6
Alvarez Jorge, A., et al., Competing Risks for Death and Cardiac Transplantation in Children With Dilated Cardiomyopathy. Circulation, 2011. 124(7): p. 814-823.
7
Wilkinson, J.D., et al., The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart failure clinics, 2010. 6(4): p. 401-vii.
8
Carvajal, K. and R. Moreno-Sánchez, Heart Metabolic Disturbances in Cardiovascular Diseases. Archives of Medical Research, 2003. 34(2): p. 89-99.
9
Holick, M.F., Vitamin D deficiency. N Engl J Med, 2007. 357(3): p. 266-81.
10
Anderson, J.L., et al., Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. The American journal of cardiology, 2010. 106(7): p. 963-968.
11
Kendrick, J., et al., 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis, 2009. 205(1): p. 255-260.
12
Skaaby, T., et al., Vitamin D status and changes in cardiovascular risk factors: a prospective study of a general population. Cardiology, 2012. 123(1): p. 62-70.
13
Wang, L., et al., Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circulation: Cardiovascular Quality and Outcomes, 2012. 5(6): p. 819-829.
14
Weyland, P.G., W.B. Grant, and J. Howie-Esquivel, Does sufficient evidence exist to support a causal association between vitamin D status and cardiovascular disease risk? An assessment using Hill’s criteria for causality. Nutrients, 2014. 6(9): p. 3403-3430.
15
Censani, M., et al., Vitamin D deficiency associated with markers of cardiovascular disease in children with obesity. Global pediatric health, 2018. 5: p. 2333794X17751773.
16
Colak, R., et al., Metabolic disturbances and cardiovascular risk factors in obese children with vitamin D deficiency. Archives de Pédiatrie, 2020.
17
Earthman, C.P., et al., The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. International journal of obesity, 2012. 36(3): p. 387-396.
18
Lee, M., et al., Inverse associations between cardiometabolic risk factors and 25‐hydroxyvitamin D in obese American children and adolescents. American Journal of Human Biology, 2016. 28(5): p. 736-742.
19
Petersen, R.A., et al., Vitamin D status is associated with cardiometabolic markers in 8–11-year-old children, independently of body fat and physical activity. British Journal of Nutrition, 2015. 114(10): p. 1647-1655.
20
Sauder, K.A., et al., Cord Blood Vitamin D Levels and Early Childhood Blood Pressure: The Healthy Start Study. Journal of the American Heart Association, 2019. 8(9): p. e011485.
21
Theodoratou, E., et al., Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. Bmj, 2014. 348: p. g2035.
22
Wang, G., et al., Vitamin D Trajectories From Birth to Early Childhood and Elevated Systolic Blood Pressure During Childhood and Adolescence. Hypertension, 2019. 74(2): p. 421-430.
23
Delvin, E.E., et al., Vitamin D Status Is Modestly Associated with Glycemia and Indicators of Lipid Metabolism in French-Canadian Children and Adolescents. The Journal of Nutrition, 2010. 140(5): p. 987-991.
24
Salo, A. and J.V. Logomarsino, Relationship of vitamin D status and cardiometabolic risk factors in children and adolescents. Pediatr Endocrinol Rev, 2011. 9(1): p. 456-62.
25
Williams, D.M., et al., Associations of 25-Hydroxyvitamin D2 and D3 with Cardiovascular Risk Factors in Childhood: Cross-Sectional Findings from the Avon Longitudinal Study of Parents and Children. The Journal of Clinical Endocrinology & Metabolism, 2012. 97(5): p. 1563-1571.
26
Manson, J.E., et al., Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine, 2018. 380(1): p. 33-44.
27
Ford, J.A., et al., Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. The American journal of clinical nutrition, 2014. 100(3): p. 746-755.
28
Barbarawi, M., et al., Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. JAMA Cardiol, 2019. 4(8): p. 765-776.
29
Ferira, A.J., et al., Vitamin D supplementation does not impact insulin resistance in black and white children. The Journal of Clinical Endocrinology & Metabolism, 2016. 101(4): p. 1710-1718.
30
Hauger, H., et al., Winter Cholecalciferol Supplementation at 55°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Children Aged 4–8 Years. The Journal of Nutrition, 2018. 148(8): p. 1261-1268.
31
Magge, S.N., et al., Vitamin D3 supplementation in obese, African-American, vitamin D deficient adolescents. Journal of clinical & translational endocrinology, 2018. 12: p. 1-7.
32
Shah, S., D.M. Wilson, and L.K. Bachrach, Large doses of vitamin D fail to increase 25-hydroxyvitamin D levels or to alter cardiovascular risk factors in obese adolescents: a pilot study. Journal of Adolescent Health, 2015. 57(1): p. 19-23.
33
Smith, T.J., et al., Winter Cholecalciferol Supplementation at 51°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Adolescents Aged 14–18 Years. The Journal of Nutrition, 2018. 148(8): p. 1269-1275.
34
Varshney, S., et al., Effect of high-dose vitamin D supplementation on beta cell function in obese Asian-Indian children and adolescents: A randomized, double blind, active controlled study. Indian Journal of Endocrinology and Metabolism, 2019. 23(5): p. 545.
35
Weishaar, R.E. and R.U. Simpson, Vitamin D3 and cardiovascular function in rats. The Journal of clinical investigation, 1987. 79(6): p. 1706-1712.
36
Oconnell, T.D. and R.U. Simpson, 1, 25-Dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. Biochemical and biophysical research communications, 1995. 213(1): p. 59-65.
37
Weishaar, R.E., et al., Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. American Journal of Physiology-Endocrinology and Metabolism, 1990. 258(1): p. E134-E142.
38
Li, Y.C., et al., 1, 25-Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin-angiotensin system. The Journal of clinical investigation, 2002. 110(2): p. 229-238.
39
Rahman, A., et al., Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. The Journal of steroid biochemistry and molecular biology, 2007. 103(3-5): p. 416-419.
40
Weber, K.T., Fibrosis and hypertensive heart disease. Current opinion in cardiology, 2000. 15(4): p. 264-272.
41
Xiang, W., et al., Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. American Journal of Physiology-Endocrinology and Metabolism, 2005. 288(1): p. E125-E132.
42
Zhou, C., et al., Calcium-independent and 1, 25 (OH) 2D3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. Kidney international, 2008. 74(2): p. 170-179.
43
Gardner, D.G., S. Chen, and D.J. Glenn, Vitamin D and the heart. American journal of physiology. Regulatory, integrative and comparative physiology, 2013. 305(9): p. R969-R977.
44
Norman, P.E. and J.T. Powell, Vitamin D and Cardiovascular Disease. Circulation Research, 2014. 114(2): p. 379-393.
45
Tishkoff, D.X., et al., Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology, 2008. 149(2): p. 558-64.
46
Somjen, D., et al., 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation, 2005. 111(13): p. 1666-71.
47
Merke, J., et al., Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest, 1989. 83(6): p. 1903-15.
48
Chen, S., et al., Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy. Circulation, 2011. 124(17): p. 1838-1847.
49
Ameri, P., et al., Relationship between vitamin D status and left ventricular geometry in a healthy population: results from the Baltimore Longitudinal Study of Aging. Journal of Internal Medicine, 2013. 273(3): p. 253-262.
50
Polat, V., et al., Low vitamin D status associated with dilated cardiomyopathy. International journal of clinical and experimental medicine, 2015. 8(1): p. 1356-1362.
51
Witte, K.K., et al., Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. Journal of the American College of Cardiology, 2016. 67(22): p. 2593-2603.
52
Prentice, A., Nutritional rickets around the world. J Steroid Biochem Mol Biol, 2013. 136: p. 201-6.
53
Brunvand, L., et al., Congestive heart failure caused by vitamin D deficiency? Acta Pædiatrica, 1995. 84(1): p. 106-108.
54
Cramm, K.J., R.A. Cattaneo, and R.D. Schremmer, An infant with tachypnea. Pediatric Emergency Care, 2006. 22(11): p. 728-731.
55
Gillor, A., et al., Congestive heart failure in an infant due to vitamin D deficiency rickets. Monatsschrift fur Kinderheilkunde, 1989. 137(2): p. 108-110.
56
Kim, B.G., et al., Dilated cardiomyopathy in a 2 month-old infant: A severe form of hypocalcemia with vitamin D deficient rickets. Korean Circulation Journal, 2010. 40(4): p. 201-203.
57
Kumar, M., et al., Vitamin D deficiency presenting with cardiogenic shock in an infant. Annals of Pediatric Cardiology, 2011. 4(2): p. 207-209.
58
Mustafa, A., J.L. Bigras, and B.W. McCrindle, Dilated cardiomyopathy as a first sign of nutritional vitamin D deficiency rickets in infancy. Canadian Journal of Cardiology, 1999. 15(6): p. 699-701.
59
Olgun, H., N. Ceviz, and B. Özkan, A case of dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. Turkish Journal of Pediatrics, 2003. 45(2): p. 152-154.
60
Price, D.I., et al., Hypocalcemic rickets: An unusual cause of dilated cardiomyopathy. Pediatric Cardiology, 2003. 24(5): p. 510-512.
61
Verma, S., et al., Hypocalcemia nutritional rickets: A curable cause of dilated cardiomyopathy. Journal of Tropical Pediatrics, 2011. 57(2): p. 126-128.
62
Yaseen, H., et al., Hypocalcemic heart failure in vitamin D deficient rickets. Pediatrie, 1993. 48(7-8): p. 547-549.
63
Eren, E., et al., A treatable cause of cardiomyopathy: Vitamin D deficiency. Guncel Pediatri, 2015. 13(2): p. 143-146.
64
Kosecik, M. and T. Ertas, Dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. Pediatrics International, 2007. 49(3): p. 397-399.
65
Amirlak, I., W. Al Dhaheri, and H. Narchi, Dilated cardiomyopathy secondary to nutritional rickets. Annals of Tropical Paediatrics, 2008. 28(3): p. 227-230.
66
Brown, J., et al., Hypocalcemic rickets and dilated cardiomyopathy: Case reports and review of literature. Pediatric Cardiology, 2009. 30(6): p. 818-823.
67
Carlton-Conway, D., et al., Vitamin D deficiency and cardiac failure in infancy. Journal of the Royal Society of Medicine, 2004. 97(5): p. 238-239.
68
Yazici, M.U., et al., Reversible Dilated Cardiomyopathy Due to Combination of Vitamin D-Deficient Rickets and Primary Hypomagnesemia in an 11-Month-Old Infant. J Pediatr Intensive Care, 2018. 7(1): p. 46-48.
69
Elidrissy, A.T.H., M. Munawarah, and K.M. Alharbi, Hypocalcemic rachitic cardiomyopathy in infants. Journal of the Saudi Heart Association, 2013. 25(1): p. 25-33.
70
Gupta, P., et al., Hypocalcemic cardiomyopathy presenting as cardiogenic shock. Annals of Pediatric Cardiology, 2011. 4(2): p. 152-155.
71
Maiya, S., et al., Hypocalcaemia and vitamin D deficiency: An important but preventable, cause of life-threatening infant heart failure. Heart, 2008. 94(5): p. 581-584.
72
Glackin, S., et al., Dilated cardiomyopathy secondary to vitamin D deficiency and hypocalcaemia in the Irish paediatric population: A case report. Ir Med J, 2017. 110(3): p. 535.
73
Hunter, L., R. Ferguson, and H. McDevitt, Vitamin D deficiency cardiomyopathy in Scotland: a retrospective review of the last decade. Arch Dis Child, 2020.
74
Yilmaz, O., et al., Dilated cardiomyopathy secondary to rickets-related hypocalcaemia: eight case reports and a review of the literature. Cardiol Young, 2015. 25(2): p. 261-6.
75
Högler, W., Complications of vitamin D deficiency from the foetus to the infant: One cause, one prevention, but who's responsibility? Best Practice and Research: Clinical Endocrinology and Metabolism, 2015. 29(3): p. 385-398.
76
Tomar, M., S. Radhakrishnan, and S. Shrivastava, Myocardial dysfunction due to hypocalcemia. Indian Pediatrics, 2010. 47(9): p. 781-783.
77
Uysal, S., A.G. Kalayci, and K. Baysal, Cardiac functions in children with vitamin D deficiency rickets. Pediatric Cardiology, 1999. 20(4): p. 283-286.
78
Sanyal, D. and M. Raychaudhuri, Infants with dilated cardiomyopathy and hypocalcemia. Indian journal of endocrinology and metabolism, 2013. 17(Suppl 1): p. S221-S223.
79
Noori, N.M., et al., 25-hydroxy Vitamin D Serum levels in Congenital Heart Disease (CHD) Children Compared to Controls. International Journal of Pediatrics, 2018. 6(8): p. 8129-8138.
80
Jammal Addin, M.B., et al., Dilated cardiomyopathy in a national paediatric population. European Journal of Pediatrics, 2019. 178(8): p. 1229-1235.
81
Peroni, D.G., et al., Vitamin D in pediatric health and disease. Pediatric Allergy and Immunology, 2020. 31(S24): p. 54-57.
82
Andiran, N., N. Yordam, and A. Ozön, Risk factors for vitamin D deficiency in breast-fed newborns and their mothers. Nutrition, 2002. 18(1): p. 47-50.
83
Ari, H., et al., A rare cause of reversible dilated cardiomyopathy: Hypocalcemia. Turk Kardiyoloji Dernegi Arsivi, 2009. 37(4): p. 266-268.
84
Csanady, M., T. Forster, and J. Julesz, Reversible impairment of myocardial function in hypoparathyroidism causing hypocalcaemia. Heart, 1990. 63(1): p. 58-60.
85
Bers, D.M., Cardiac excitation–contraction coupling. Nature, 2002. 415(6868): p. 198-205.
86
Weber, K.T., R.U. Simpson, and L.D. Carbone, Vitamin D and calcium dyshomoeostasis-associated heart failure. Heart, 2008. 94(5): p. 540-1.
87
Szent-Györgyi, A.G., Calcium regulation of muscle contraction. Biophysical journal, 1975. 15(7): p. 707-723.
88
De Boland, A.R. and R.L. Boland, Non-genomic signal transduction pathway of vitamin D in muscle. Cellular Signalling, 1994. 6(7): p. 717-724.
89
Weishaar, R.E. and R.U. Simpson, Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol, 1987. 253(6 Pt 1): p. E675-83.
90
Weber, K.T., W.B. Weglicki, and R.U. Simpson, Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovascular Research, 2009. 81(3): p. 500-508.
91
Ogino, K., et al., Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab, 2002. 87(10): p. 4722-7.
92
Saetrum Opgaard, O. and P.H. Wang, IGF-I is a matter of heart. Growth Horm IGF Res, 2005. 15(2): p. 89-94.
93
Troncoso, R., et al., New insights into IGF-1 signaling in the heart. Trends in Endocrinology & Metabolism, 2014. 25(3): p. 128-137.
94
Munns, C.F., et al., Global consensus recommendations on prevention and management of nutritional rickets. Hormone Research in Paediatrics, 2016. 85(2): p. 83-106.
95
Hollis, B.W., et al., Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial. Pediatrics, 2015. 136(4): p. 625-34.
96
ORIGINAL_ARTICLE
The Effects of Intravenous Immunoglobulin on Coronary Artery Abnormalities in Children With Kawasaki Disease
Background: Kawasaki disease (KD) is an acute systemic vasculitis in childhood, with a strong effect on the heart. The present study aimed to evaluate the effects of intravenous immunoglobulin (IVIG) on coronary artery abnormalities in children with KD. Methods: This study was performed on 101 children with KD between 2004 and 2019. Echocardiography was used to assess coronary artery abnormalities. A coronary artery was considered abnormal if the internal lumen diameter exceeded 2 mm in infants, 3 mm in children aged between 2 and 5 years, and 4 mm in children older than 5 years. Data analysis was done using the SPSS software, version 22. A P value less than 0.05 was considered statistically. Results: Before IVIG administration, abnormal left coronary arteries were reported in 21 children. However, 2, 6, and 12 months following IVIG administration, the number of children with left coronary artery abnormalities dropped to 5, 2, and 1, respectively. Before IVIG administration, abnormal right coronary arteries were reported in 13 patients. Nonetheless, 2, 6, and 12 months after IVIG administration, the number of patients with right coronary artery abnormalities fell to 5, 1, and 1, respectively. Conclusions: IVIG administration in our children with KD significantly affected left and right coronary artery abnormalities after 6 months, with the effect being stronger in the left coronary artery. (Iranian Heart Journal 2022; 23(1): 172-183)
http://journal.iha.org.ir/article_142611_7f9bd4a23ada1519599311672b4b85ce.pdf
2022-01-01
172
183
Kawasaki disease
intravenous immunoglobulin
Coronary Artery
children
Noor Mohammad
Noori
dr_noori_cardio@yahoo.com
1
Children and Adolescent Health Research Center, Research Institute of cellular and Molecular Science in Infectious Diseases , Zahedan University of Medical Science's, Zahedan, IR Iran.
AUTHOR
Ali
Pezzhan
pezhhan_ali@yahoo.com
2
Department of Population Study, School of Sociology, Islamic Azad University of Iran, Central Tehran Branch, Tehran, IR Iran.
AUTHOR
Alireza
Teimouri
alirezateimouri260@gmail.com
3
Children and Adolescent Health Research Center, Research Institute of cellular and Molecular Science in Infectious Diseases , Zahedan University of Medical Science's, Zahedan, IR Iran.
LEAD_AUTHOR
Dyer T, Dancey P, Martin J, Shah S. Torticollis as Presentation for Atypical Kawasaki Disease Complicated by Giant Coronary Artery Aneurysms. Case reports in pediatrics. 2018; 2018.
1
Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child.2015;100(11):10848.
2
Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, Uehara R, Kotani K, Yanagawa H. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015; 25(3):23945.
3
Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL, Yu JJ, Choi JW, Lee KY. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012–2014. The Pediatric infectious disease journal. 2017 May 1; 36(5):482-5.
4
Wu MH, Lin MT, Chen HC, Kao FY, Huang SK. Postnatal risk of acquiring Kawasaki disease: a nationwide birth cohort database study. J Pediatr. 2017; 180:8086.e2.
5
Ozdemir H, Ciftci E, Tapisiz A, Ince E, Tutar E, Atalay S, Dogru U. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. J Trop Pediatr. 2010; 56(4):2602.
6
Asadi-Pooya AA, Borzoee M, Amoozgar H. The experience with 113 patients with Kawasaki disease in Fars Province, Iran. Turk J Pediatr. 2006; 48(2):109114.
7
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25; 135(17):e927-99.
8
Chaiyarak K, Durongpisitkul K, Atta T, Soongswang J, Laohaprasitiporn D, Nana A. Clinical manifestations of Kawasaki disease: what are the significant parameters?. Asian Pacific journal of allergy and immunology. 2009 Jun 1; 27(2-3):131.
9
Campbell AJ, Burns JC. Adjunctive therapies for Kawasaki disease. Journal of Infection. 2016; 72:S1-5.
10
Menikou S, Langford PR, Levin M. Kawasaki disease: the role of immune complexes revisited. Frontiers in immunology. 2019; 10.1156.
11
Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. PediatrRheumatol Online J. (2014) 12:26. doi: 10.1186/1546-0096-12-26.
12
Noguchi S, Saito J, Kudo T, Hashiba E, Hirota K. Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: Case series. JA clinical reports. 2018 Dec 1; 4(1):25.
13
Lin MT, Wu MH. The global epidemiology of Kawasaki disease: Review and future perspectives. Global cardiology science & practice. 2017 Oct 31; 2017(3).
14
Song MS. Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease. Korean journal of pediatrics. 2019 Apr;62(4):119.
15
Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. The Journal of pediatrics. 2000 Aug 1; 137(2):250-2.
16
Kil HR, Yu JW, Lee SC, Rhim JW, Lee KY. Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea. Pediatric Rheumatology. 2017 Dec; 15(1):60.
17
Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease. Pediatric Rheumatology. 2019 Dec 1; 17(1):53.
18
Bal AK, Prasad D, Pamintuan MA, Mammen-Prasad E, Petrova A. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Pediatrics & Neonatology. 2014 Oct 1; 55(5):387-92.
19
Binder E, Griesmaier E, Giner T, Sailer-Höck M, Brunner J. Kawasaki disease in children and adolescents: clinical data of Kawasaki patients in a western region (Tyrol) of Austria from 2003–2012. Pediatric Rheumatology. 2014 Dec;12(1):37.
20
Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, Qian W, Qian G, Qin L, Lv H. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. European journal of pediatrics. 2018 Aug 1; 177(8):1279-92.
21
Shah SA, Mahmud S. KAWASAKI DISEASE EXPERIENCE AT TERTIARY CARE HOSPITAL RAWALPINDI, PAKISTAN. Pakistan Armed Forces Medical Journal. 2018 Oct 1(5):1143.48
22
Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 2012; 129:e291–7.
23
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606–2612.
24
Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663- 75
25
Keum SW, Hur SM, Youn YS, Rhim JW, Suh JS, Lee KY, et al Changes in acute poststreptococcal glomerulonephritis: an observation study at a single Korean hospital over two decades. Child Kidney Dis. 2015; 19:112–7.
26
Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237–240.
27
Oates‐Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews. 2003(4).
28
ORIGINAL_ARTICLE
Correlation Between Ventricular Perfusion Ischemia and Left Ventricular Dyssynchrony in Phase Analysis by Gated SPECT MPI
Background: The gated single-photon emission computed tomography (Gated SPECT), myocardial perfusion imaging (MPI) is one of the most accurate methods to evaluate the extent of myocardial ischemia. The present study aimed to assess the correlation between the severity of ischemia and left ventricular dyssynchrony in phase analysis with GATED SPECT MPI by comparing the indices of perfusion, function, and phase analysis in stress and rest phases.
Methods: This cross-sectional study was performed on patients referred for Gated SPECT MPI. Fifty-six patients with ischemic heart disease based on Gated SPECT MPI and invasive coronary angiography were included. Parameters regarding myocardial perfusion and function in stress and rest conditions and coronary vessel parameters were assessed. Phase analysis indices, including phase standard deviation (PSD), phase histogram bandwidth (PHB), and entropy, based on Gated SPECT MPI (with the QGS software) were also evaluated
Results: Phase parameters, including PSD, PHB, and entropy, showed a good correlation with the severity of ischemia in stress conditions (P<0.05).
Conclusions: Scintigraphic indices of ischemia severity were highly correlated with phase analysis indices by Gated SPECT MPI. Therefore, an evaluation of these indices may accurately estimate systolic ventricular dyssynchrony, predict relative poor outcomes of cardiac ischemic events, and determine priorities for interventional cardiologists. (Iranian Heart Journal 2022; 23(1): 184-191)
http://journal.iha.org.ir/article_142612_20737b18203759671608a7bb3f7b8978.pdf
2022-01-01
184
191
DYSSYNCHRONY
Phase analysis
Ischemia
Gated SPECT
MPI
Feridoon
Rastgou
f_rastgou@yahoo.com
1
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Masume
Soltanabadi
soltanabadimasume@gmail.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hassan
Firoozabadi
shfirouz@gmail.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ahmad
Bitarafan-Rajabi
bitarafan@hotmail.com
4
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Hadi
Malek
drhmalek@gmail.com
5
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Nahid
Yaghoobi
nahidyaghoobi46@gmail.com
6
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hooman
Bakhshandeh
hooman.bakhshande@gmail.com
7
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Raheleh
Hedayati
dochedayati@gmail.com
8
Rasule Akram General Hospital, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Psota M, Bandosz P, Goncalvesova E, Avdičová M, Pšenková MB, Studenčan M, et al. Explaining the decline in coronary heart disease mortality rates in the Slovak Republic between 1993-2008. PloS one. 2018; 13(1).
1
Rahimi K, Lam CS, Steinhubl S. Cardiovascular disease and multimorbidity: A call for interdisciplinary research and personalized cardiovascular care. PLoS medicine. 2018; 15(3).
2
Liu Y, Jiang Y, Yang X, Geng B, Liu Y, Shang X, et al. Limited prognostic value of myocardial viability assessment in patients with coronary artery diseases and severe left ventricular dysfunction. Journal of thoracic disease. 2018; 10(4):2249.
3
Claridge S, Briceno N, Chen Z, De Silva K, Modi B, Jackson T, et al. Changes in contractility determine coronary haemodynamics in dyssynchronous left ventricular heart failure, not vice versa. IJC heart & vasculature. 2018; 19:8-13.
4
Gimelli A, Liga R, Genovesi D, Giorgetti A, Kusch A, Marzullo P. Association between left ventricular regional sympathetic denervation and mechanical dyssynchrony in phase analysis: a cardiac CZT study. European journal of nuclear medicine and molecular imaging. 2014; 41(5):946-55.
5
Chen J, Garcia E, Henneman M, Bax J, Boogers M, Trimble M, et al. Measuring left ventricular mechanical dyssynchrony from ECG-gated SPECT myocardial perfusion imaging. Minerva cardioangiologica. 2008; 56(2):227-35.
6
Chen J, Garcia EV, Lerakis S, Henneman MM, Bax JJ, Trimble MA, et al. Left Ventricular Mechanical Dyssynchrony as Assessed by Phase Analysis of ECG‐Gated SPECT Myocardial Perfusion Imaging. Echocardiography. 2008; 25(10):1186-94.
7
Keida T, Ohira H, Fujita M, Chinen T, Nakamura K, Kato T, et al. Quantitative assessment of dyssynchrony using ECG-gated SPECT myocardial perfusion imaging prior to and following cardiac resynchronization therapy. Circulation Journal. 2009:0901070225-.
8
Henneman MM, Chen J, Ypenburg C, Dibbets P, Bleeker GB, Boersma E, et al. Phase analysis of gated myocardial perfusion single-photon emission computed tomography compared with tissue Doppler imaging for the assessment of left ventricular dyssynchrony. Journal of the American College of Cardiology. 2007; 49(16):1708-14.
9
Marsan NA, Henneman MM, Chen J, Ypenburg C, Dibbets P, Ghio S, et al. Left ventricular dyssynchrony assessed by two three-dimensional imaging modalities: phase analysis of gated myocardial perfusion SPECT and tri-plane tissue Doppler imaging. European journal of nuclear medicine and molecular imaging. 2008; 35(1):166-73.
10
Hekmat S, Rastgoo F, Omrani G, Yaghoobi N, Baghaie R, Firoozabadi H, et al. Comparison of the myocardial perfusion and wall motion results by ECG-Gated 99mTc-MIBI SPECT, before and after CABG for evaluation of myocardial viability [Persian]. Iranian Journal of Nuclear Medicine. 2003; 11(1):29-32.
11
Malek H, Rayegan F, Firoozabadi H, Rastgoo F, Haghjoo M, Bakhshandeh H, et al. Determination of normal ranges of regional and global phase parameters using gated myocardial perfusion imaging with Cedars-Sinai’s QGS software. Iranian Journal of Nuclear Medicine. 2018; 26(1):16-21.
12
Cho S-G, Jabin Z, Park KS, Kim J, Kang S-R, Kwon SY, et al. Clinical values of left ventricular mechanical dyssynchrony assessment by gated myocardial perfusion SPECT in patients with acute myocardial infarction and multivessel disease. European journal of nuclear medicine and molecular imaging. 2017; 44(2):259-66.
13
Goldberg AS, Alraies MC, Cerqueira MD, Jaber WA, AlJaroudi WA. Prognostic value of left ventricular mechanical dyssynchrony by phase analysis in patients with non-ischemic cardiomyopathy with ejection fraction 35-50% and QRS< 150 ms. Journal of Nuclear Cardiology. 2014; 21(1):57-66.
14
Uebleis C, Hellweger S, Laubender RP, Becker A, Sohn H-Y, Lehner S, et al. Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy. European journal of nuclear medicine and molecular imaging. 2012; 39(10):1561-9.
15
Trimble MA, Borges-Neto S, Honeycutt EF, Shaw LK, Pagnanelli R, Chen J, et al. Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. Journal of nuclear cardiology. 2008; 15(5):663-70.
16
Garcia EV, Slomka P, Moody JB, Germano G, Ficaro EP. Quantitative Clinical Nuclear Cardiology, Part 1: Established Applications. Journal of Nuclear Medicine. 2019; 60(11):1507-16.
17
Malek H, Hedayati R, Yaghoobi N, Behnia M, Rastgou F, Bitarafan Rajabi A, et al. The relationship between retinopathy in diabetes mellitus type 2 and severity and extent of myocardial ischemia in myocardial perfusion imaging. Iranian Heart Journal. 2013; 13(4):6-14.
18
Bitarafan-Rajabi A, Rastgou F, Hosseini S, Firoozabadi H, Malek H, Amouzadeh H, et al. Assessment of myocardial viability in patients with left ventricular dysfunction: Correlation between CT-based attenuation correction and uncorrected quantification analysis in thallium201 (201Tl) rest-redistribution SPECT study. Iranian Heart Journal. 2013:15-20.
19
Rastgou F, Shojaeifard M, Amin A, Ghaedian T, Firoozabadi H, Malek H, et al. Assessment of left ventricular mechanical dyssynchrony by phase analysis of gated-SPECT myocardial perfusion imaging and tissue Doppler imaging: comparison between QGS and ECTb software packages. Journal of Nuclear Cardiology. 2014; 21(6):1062-71.
20
ORIGINAL_ARTICLE
Intraoperative Measurement of the Pulmonary Artery Pressure: Is It Reliable?
Background: Measurement of pulmonary artery pressure (PAP) is important for therapeutic planning in most types of structural heart diseases. The standard route for measuring PAP is cardiac catheterization. Nevertheless, in some cases, abnormal cardiac structures do not allow for advancing the catheter into the pulmonary artery. Measurement of pulmonary venous wedge pressure is another way, but it is not possible in some cases. During cardiac surgery, it is possible to measure PAP by directly entering a small needle into the pulmonary artery. This study aimed to evaluate the accuracy of PAP measurement during cardiac surgery in patients in a surgical environment.
Methods: The study enrolled 105 consecutive patients with congenital heart defects in whom cardiac catheterization was done before cardiac surgery. Systolic and diastolic pressures of the aorta and the pulmonary artery were measured and recorded both during catheterization and during cardiac surgery, and their correlations were assessed.
Results: Most of the pressures measured during cardiac surgery were lower than those measured during catheterization; nevertheless, no linear or other clear associations were found between them. There was no meaningful correlation concerning the amount of change between systemic and pulmonary pressures.
Conclusions: PAP significantly changes during general anesthesia and with an opened chest cage. PAP measured during surgery could not be relied upon for critical decisions such as univentricular approaches. (Iranian Heart Journal 2022; 23(1): 192-197)
http://journal.iha.org.ir/article_142613_0e1d72bcffca0bb0793925be9df2e65b.pdf
2022-01-01
192
197
Congenital heart
children
Pulmonary artery pressure
Cardiac Surgery
Mohammad
Dalili
drdalili@yahoo.com
1
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Reza
Abbaszadeh
rasemani95@yahoo.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Abutaleb
Mohammadi
mohammadi.ali97@yahoo.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Ali
Sadeghpour-Tabaei
alisadeghpour@yahoo.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mahmood
Sheikh Fathollahi
mamoosh502002@yahoo.com
5
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Cetta F, Dearani J, O'Leary P, Driscoll D, Tricuspid Valve Disorders: Atresia, Dysplasia, and Ebstein Anomaly; in Allen H, Shaddy R, Penny D et al; Moss & Adams’ Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult; 9th edition 2016, wolters Kluwer, 957-958
1
van der Ven JPG, van den Bosch E, Bogers AJCC, Helbing WA. State of the art of the Fontan strategy for treatment of univentricular heart disease. F1000Res. 2018;7:F1000 Faculty Rev-935. Published 2018 Jun 27. doi:10.12688/f1000research.13792.1
2
Hill KD, Janssen D, Ohmstede DP, Doyle TP. Pulmonary venous wedge pressure provides a safe and accurate estimate of pulmonary arterial pressure in children with shunt-dependent pulmonary blood flow. Catheter Cardiovasc Interv. 2009 Nov 1;74(5):747-52. doi: 10.1002/ccd.22084. PMID: 19496126.
3
Earing M, Hagler D, Edwards W. Univentricular Atrioventricular Connection, in Allen H, Shaddy R, Penny D et al; Moss & Adams’ Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult; 9th edition 2016, wolters Kluwer, 1235
4
Akintoye, E., Veldtman, G.R., Miranda, W.R., Connolly, H.M. and Egbe, A.C. (2019), Optimum age for performing Fontan operation in patients with univentricular heart. Congenital Heart Disease, 14: 138-139. doi:10.1111/chd.12690
5
Mohammad Nijres B, Murphy JJ, Diab K, Awad S, Abdulla R. Routine Cardiac Catheterization Prior to Fontan Operation: Is It a Necessity? Pediatric Cardiology. 2018 Apr 1;39(4):818-823. https://doi.org/10.1007/s00246-018-1825-8
6
Arda Ozyuksel, Baran Simsek, Omer Ozden, et al. Fontan Procedure in Patients with Preoperative Mean Pulmonary Artery Pressure Over 15 mmHg. Authorea. September 05, 2020.
7
Ohuchi H. Where Is the "Optimal" Fontan Hemodynamics?. Korean Circ J. 2017;47(6):842-857. doi:10.4070/kcj.2017.0105
8
Parasuraman S, Walker S, Loudon BL, et al. Assessment of pulmonary artery pressure by echocardiography-A comprehensive review. Int J Cardiol Heart Vasc. 2016;12:45-51. Published 2016 Jul 4. doi:10.1016/j.ijcha.2016.05.011
9
Melzig C, Wörz S, Egenlauf B, Partovi S, Rohr K, Grünig E, Kauczor HU, Heussel CP, Rengier F. Combined automated 3D volumetry by pulmonary CT angiography and echocardiography for detection of pulmonary hypertension. Eur Radiol. 2019 Nov;29(11):6059-6068. doi:10.1007/s00330-019-06188-7. Epub 2019 Apr 8. PMID: 30963276.
10
Rengier F, Wörz S, Melzig C, Ley S, Fink C, Benjamin N, Partovi S, von Tengg-Kobligk H, Rohr K, Kauczor HU, Grünig E. Automated 3D Volumetry of the Pulmonary Arteries based on Magnetic Resonance Angiography Has Potential for Predicting Pulmonary Hypertension. PLoS One. 2016 Sep 14;11(9):e0162516. doi: 10.1371/journal.pone.0162516. PMID: 27626802; PMCID: PMC5023190.]
11
Denault A, Deschamps A, Tardif JC, Lambert J, Perrault L. Pulmonary hypertension in cardiac surgery. Curr Cardiol Rev. 2010;6(1):1-14. doi:10.2174/157340310790231671
12
Robitaille A, Denault AY, Couture P, Bélisle S, Fortier A, Guertin MC, Carrier M, Martineau R. Importance of relative pulmonary hypertension in cardiac surgery: the mean systemic-to-pulmonary artery pressure ratio. J Cardiothorac Vasc Anesth. 2006 Jun;20(3):331-9. doi: 10.1053/j.jvca.2005.11.018. Epub 2006 Apr 19. PMID: 16750732.
13
ORIGINAL_ARTICLE
Cardiac Troponin Variation Trends in Patients With Acute Pulmonary Embolism
Background: Pulmonary embolism (PE) is among the deadliest diseases in that it can cause sudden death. The present study aimed to determine cardiac troponin I (CTnI) variation trends in patients with acute PE referred to Rajaie Cardiovascular Medical and Research Center.
Methods: This cross-sectional descriptive-analytical study consecutively enrolled 54 patients with acute PE. Variation trends of CTnI were measured in the study population at 5 different time points: upon admission and subsequently 8, 24, 48, and 72 hours post-admission. The relationships between CTnI variation trends and computed tomography angiography, echocardiography, and electrocardiography findings were investigated. CTnI variation trends were compared between a group undergoing catheter-directed thrombolysis (CDT) and a group receiving the conventional anticoagulant treatment. The data were analyzed using the SPSS software, version 20.
Results: A reduction was observed in the CTnI variation trends of all the samples. Both groups exhibited a decline in CTnI levels, but the slope of this reduction was steeper in the CDT group (P=0.04). Additionally, a significant relationship was also detected between CTnI reduction and right ventricular function improvement (P=0.04). No significant association was observed between systolic pulmonary artery pressure changes and CTnI variation trends.
Conclusions: The results indicated a significant relationship between reduced CTnI levels and improved right ventricular function. Additionally, the CDT group showed a significant fall in the CTnI level compared with the anticoagulant-only group. (Iranian Heart Journal 2022; 23(1): 198-204)
http://journal.iha.org.ir/article_142614_b0b1709f0d6db2bd11b31abf8d53f396.pdf
2022-01-01
198
204
pulmonary thromboembolism
Anticoagulant
Cardiac troponin I
Mohammad Mehdi
Peighambari
mehdipei@gmail.com
1
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad Javad
Alemzadeh-Ansari
mj.aansari@gmail.com
2
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Golnoush
Yaghoubzadeh
ygolnoush@yahoo.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Sepideh
Masteri Farahani
farahani.sepideh90@gmail.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Jenab, Y., Lotfi-Tokaldany, M., Alemzadeh-Ansari, M.-J.Email Author, Seyyedi, S.R., Shirani, S., Soudaee, M., Ghaffari-Marandi, N., Correlates of Syncope in Patients with Acute Pulmonary Thromboembolism, Clinical and Applied Thrombosis/Hemostasis, Volume 21, Issue 8, 1 November 2015, Pages 772-776
1
Jenab Y, Alemzadeh-Ansari MJ, Fehri SA, Ghaffari-Marandi N, Jalali A. Effect of delay in hospital presentation on clinical and imaging findings in acute pulmonary thromboembolism. The Journal of emergency medicine. 2014 Apr 1; 46(4):465-71.
2
Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102:211-17.
3
Jenkins PO, Sultanzadeh J, Bhagwat M, et al. Should thrombolysis have a greater role in the management of pulmonary embolism? Clin Med 2009; 9:431-5.
4
Lankeit M, Konstantinides S. Thrombolysis for pulmonary embolism: past, present and future. Thromb Haemost 2010; 103:877-83.
5
Orde MM, Puranik R, Morrow PL, et al. Myocardial pathology in pulmonary thromboembolism. Heart 2011; 97:1695-9.
6
Demir N, Ekim N, Oguzulgen IK, Bukan N (2012) the Value of Cardiac Troponins in Diagnosis and Differential Diagnosis of Pulmonary Embolism. J Pulmon Resp Med 2:134.
7
Lauer B, Niederau C, Kühl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997; 30:1354–1359.
8
Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. Circulation. 1997; 95:163–168.
9
Emile Ferrari, Pamela Moceri, Christophe Crouzet, Denis Doyen, Pierre Cerboni. Timing of troponin I measurement in pulmonary embolism; Heart 2012 98: 732-735.
10
Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction; J Am Coll Cardiol. 2000 Nov 1; 36(5):1632-6.
11
Amorim S, Dias P, Rodrigues RA, et al. Troponin I as a marker of right ventricular dysfunction and severity of pulmonary embolism; Rev Port Cardiol. 2006 Feb; 25(2):181-6.
12
Tavana S, Panahi Y, et al., coronary troponin I levels in the patients with acute pulmonary embolism and its relationship with right ventricular dysfunction; Journal of Mazanradan University of medical sciences; June 2009, (19), 70, 72-75
13
Margato R, Carvalho S, et al. Cardiac troponin I levels in acute pulmonary embolism; Rev Port Cardiol. 2009 Nov; 28(11):1213-22.
14
Gonca Kilinc, Omer Tamer Dogan, et al. Significance of serum cardiac troponin I levels in pulmonary embolism; J Thorac Dis. 2012 Dec; 4(6): 588–593.
15
Ozsu S, Abul Y, Orem A, Oztuna F, Bulbul Y, Yaman H, Ozlu T. Predictive value of troponins and simplified pulmonary embolism severity index in patients with normotensive pulmonary embolism. Multidisciplinary respiratory medicine. 2013 Dec 1;8(1):34.
16
ORIGINAL_ARTICLE
Effectiveness of the Self-report Pain Intensity Scale in Pain Control After Coronary Artery Bypass Surgery
Background: Pain following cardiac surgery is common, and pain assessment is a precondition for adequate pain management. We designed this study to evaluate the effectiveness of pain control using the self-report pain intensity scale during the postoperative period after coronary artery bypass surgery in the cardiac ICU.
Methods: Of 160 patients scheduled for elective coronary revascularization, 154 patients were included in this prospective, double-blind clinical trial. The pain management program was performed on conscious patients for 48 hours. The study population was randomly divided into 2 groups. One group received analgesics as needed, based on conventional nurse-controlled analgesia (the NCA group; n=77), and the other group received analgesics based on the pain intensity score determined using the linear numerical rating scale (NRS group; n=77). In both groups, opioid and non-opioid analgesic consumption and satisfaction levels with pain relief were recorded.
Results: The use of the self-report pain intensity scale led to an increase in the number of recipients of analgesic drugs and a decrease in their opioid/analgesic consumption during a 48-hour period in the NRS group. Satisfaction levels with pain relief were higher in the NRS group than in the NCA group (maximum satisfaction =43 [55.8%] vs 9 [11.8%], respectively; P=0.0001).
Conclusions: The findings of this study showed the efficacy of the self-report pain intensity scale in controlling patients’ pain, using adequate and appropriate analgesics, prescribing accurate amounts of medication based on patients’ pain, and increasing patients’ satisfaction with pain relief. (Iranian Heart Journal 2022; 23(1): 205-213)
http://journal.iha.org.ir/article_142615_e356e0353d7f18ebd78fced3e3818c5c.pdf
2022-01-01
205
213
Pain measurement tool
Pain management
Cardiac Surgery
Intensive Care Unit
Nahid
Aghdaii
aghdaii@yahoo.com
1
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Rasoul
Azarfarin
azarfarinr@gmail.com
2
Cardio-oncology Research Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohsen
Ziyaeifard
m.ziyaeifard@yahoo.com
3
Cardio-oncology Research Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Zahra sadat
Navabi
navabi@yahoo.com
4
Ayatollah Kashani Haspital, Isfahan University of Medical Sciences, Isfahan, IR Iran.
AUTHOR
Zahra
Faritous
s.faritous@yahoo.com
5
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Brunner LS, Smeltzer SCC, Bare BG, Hinkle JL, Cheever KH. Brunner & Suddarth’s Textbook of Medical-surgical Nursing: Suzanne C. Lippincott Williams & Wilkins; 2014. 321-327
1
Choiniere, J. Watt-Watson, J.C. Victor, et al., Prevalence of and risk factors for persistent postoperative nonanginal pain after cardiac surgery: a 2-year prospective multicentre study, Can. Med. Assoc J 2014 186 (7) E213–E223, https://doi.org/10.1503/cmaj.131012.
2
V, Mirmansouri.A, Mohammadzadeh Jouryabi.A , Naderi Nabi.B, Kanani.GhR , Nassiri Sheikhani.N, Atrkarroushan.Z, Ghazanfar.S. Comparing the Effectiveness of Patient Control Analgesia Pump and Bolus Morphine in Controlling Pain After Cardiopulmonary Bypass Graft Surgery. Anesth Pain Med. 2017 October; 7(5):e12756. doi:10.5812/aapm.12756.
3
Hamid M, Gangwani AL, Akhtar MI. A Quality Improvement Survey to Assess Pain Management in Cardiac Surgery Patients. Open J Anesthesiol. 2015;05(05):105–1 doi:10.4236/ojanes.2015.55020.
4
Coventry LL, Siffleet JM, Williams AM. Review of analgesia use in the intensive care unit after heart surgery. Crit Care Resusc 2006; 8(2): 135-40.
5
N; Yazdanian; Faritus.SZ. Sedative Efficacy of Propofol in Patients Intubated/Ventilated after Coronary Artery Bypass Graft Surgery. Anesth Pain Med. 2014 February; 4(1): e17109. DOI:10.5812/aapm.17109
6
Greisen, T. Grøfte, P.O. Hansen, T.S. Jensen, H. Vilstrup, Acute non-traumatic pain increases the hepatic amino- to urea-N conversion in normal man, J. Hepatol. 1999 31 (4) 647–655, http://www.ncbi.nlm.nih.gov/pubmed/10551388. Accessed June 16, 2018.
7
T. Mangano, D. Siliciano, M. Hollenberg, et al., Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group, Anesthesiology 1992 76 (3) 342–353, http://www.ncbi.nlm.nih.gov/pubmed/1531742. Accessed June 16, 2018.
8
Huang AP, Sakata RK. [Pain after sternotomy - review]. Rev Bras Anestesiol. 2016;66(4):395–401. doi:10.1016/j.bjan.2014.09.003. [PubMed: 25796483].
9
Lahtinen P, Kokki H,HynynenM. Pain after cardiac surgery: a prospective cohort study of 1-year incidence and intensity. Anesthesiology. 2006;105(4):794–800. [PubMed: 17006079].
10
Totonchi Z, Seifi S, Chitsazan M, Alizadeh Ghavidel A, Baazm F, Faritus SZ. Pain location and intensity during the first week following coronary artery bypass graft surgery. Anesth Pain Med. 2014;4(1):e10386. doi:10.5812/aapm.10386. [PubMed: 24660142].
11
Tsang J, Brush B. Patient-controlled analgesia in postoperative cardiac surgery. Anaesth Intensive Care. 1999;27(5):464–70. [PubMed:10520385].
12
Diby M, Romand JA, Frick S, Heidegger CP,Walder B. Reducing pain in patients undergoing cardiac surgery after implementation of a quality improvement postoperative pain treatment program. J Crit Care.2008;23(3):359–71. doi:10.1016/j.jcrc.2007.11.005. [PubMed: 18725042].
13
Jayakumar, M. Borrelli, Z. Milan, G. Kunst, D. Whitaker. Optimising pain management protocols following cardiac surgery:A protocol for a national quality improvement study. International Journal of Surgery Protocols 2019 14: 1–8, (http://creativecommons.org/licenses/by/4.0/).
14
Parizad R, Abdolahzadeh F, Mousavi-Shabestari M. Pain after Cardiac Surgery: A Review of the Assessment and Management. Crescent J Med Biol Sci. 2014;1(4):113–7.
15
Rafiq S, Steinbruchel DA,Wanscher MJ, Andersen LW,Navne A, Lilleoer NB, et al. Multimodal analgesia versus traditional opiate based analgesia after cardiac surgery, a randomized controlled trial. J Cardiothorac Surg. 2014;9:52. doi: 10.1186/1749-8090-9-52. [PubMed: 24650125].
16
E. Bigeleisen, N. Goehner, Novel approaches in pain management in cardiac surgery, Curr. Opin. Anaesthesiol. 2015 28 (1): 89–94, https://doi.org/ 10.1097/ACO.0000000000000147.
17
E. Macintyre, S.M. Walker, The scientific evidence for acute pain treatment, Curr. Opin. Anaesthesiol. 2010 23 (5): 623–628, https://doi.org/10.1097/ ACO.0b013e32833c33ed.
18
M, Mehrabanian.MJ, Faritus.SZ , Khazaei Koohpar.M, Ferasatkish.R, Hosseinnejad.H, et al. Premedication With Oral Pregabalin for the Prevention of Acute Postsurgical Pain in Coronary Artery Bypass Surgery. Anesth Pain Med. 2015 Feb; 5(1): e24837. doi: 10.5812/aapm.24837
19
Yorke J, Wallis M, McLean B. Patients' perceptions of pain management after cardiac surgery in an Australian critical care unit. Heart Lung 2004; 33(1): 33-41.
20
Diby M, Romand JA, Frick S, Heidegger CP, Walder B. Reducing pain in patients undergoing cardiac surgery after implementation of a quality improvement postoperative pain treatment program. J Crit Care 2008; 23(3): 359-71.
21
Watt-Watson J, Stevens B, Garfinkel P, Streiner D, Gallop R. Relationship between nurses' pain knowledge and pain management outcomes for their postoperative cardiac patients. J Adv Nurs 2001; 36(4): 535-45.
22
Watt-Watson J, Stevens B, Katz J, Costello J, Reid GJ, David T. Impact of preoperative education on pain outcomes after coronary artery bypass graft surgery. Pain 2004; 109(1-2): 73- 85.
23
Barr J, Fraser GL, Puntillo K, Ely EW et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41: 263–306
24
M, Azarfarin.R, Totonchi.Z, Tavakoli.F, Alizadehasl.A , Teymouri.M . Comparison of Two Pain Assessment Tools, "Facial Expression" and "Critical Care Pain Observation Tool" in Intubated Patients After Cardiac Surgery. Anesth Pain Med 2016 Jan 18; 6(1):e33434. doi:10.5812/aapm.33434
25
Payen JF, Chanques G, Mantz J et al. Current practices in sedation and analgesia for mechanicall ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007; 106: 687–95)
26
DAS-Taskforce (2015) Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine. Revision 2015 (DAS-Guideline)
27
Klein DG,, Dumpe M,, Katz E,, et al. Pain assessment in the intensive care unit: Development and psychometric testing of the nonverbal pain assessment tool. Heart Lung. 2010; 39((6):):521-–528.. [PubMed] [Google Scholar]
28
C , Gélinas.C , Michaud.C. Impact of the Implementation of the Critical-Care Pain Observation Tool (CPOT) on Pain Management and Clinical Outcomes in Mechanically Ventilated Trauma Intensive Care Unit Patients: A Pilot Study. Journal of Trauma Nursing. 2011 18(1):52–60, JANUARY/MARCH. DOI:10.1097/JTN.0b013e3181ff2675
29
Topolovec-Vranic, J., Canzian, S., Innis, J., Pollmann-Mudryj, M. A., Mcfarland, A. W. & Baker, A. J. Patient satisfaction and documentation of pain assessments and management after implementingthe adult nonverbal pain scale. American Journal of Critical Care, 2010 19, 345-354.
30
Sattari M, Baghdadchi ME, Kheyri M, Khakzadi H, Ozar Mashayekhi S. Study of patient pain management after heart surgery. Adv Pharm Bull. 2013; 3(2):373–7.
31
Jahangiri Fard.A; Babaee.T; Alavi.SM; NasiriAA; Ghoreishi.SMM; Noori.NM; Mahjoubifard.M. Intravenous Patient-Controlled Remifentanil Versus Paracetamol in Post- Operative Pain Management in Patients Undergoing Coronary Artery Bypass Graft Surgery. Anesth Pain Med. 2014 December; 4(5): e19862. DOI: 10.5812/aapm.19862
32
Eremenko AA, Kuslieva EV. [Analgesic and opioid-sparing effects of intravenous paracetamol in the early period after aortocoronary bypass surgery]. Anesteziol Reanimatol. 2008(5):11–4.
33
Mccarthy, D., Reichert, D., Vaidiyanathan, S., Ranganath, A. & Beleil, M. Review of post operative analgesia in cardiac surgery patients in the intensive care unit: 14AP9.1. European Journal of Anaesthesiology (EJA) 2010 27, 214.
34
ORIGINAL_ARTICLE
A Case of Myocardial Infarction With Nonobstructive Coronary Arteries due to the Compressive Effects of a Type B Thymoma With Internal Hemorrhage
Our case was a 45-year-old woman who presented with a chief complaint of intermittent typical chest pain. In electrocardiography, ST-elevation in the lateral leads was observed. Echocardiography showed mild left ventricular systolic dysfunction with hypokinesia in the anteroapical segment. Coronary angiography was normal, and chest computed tomography showed a large mediastinal mass without any compression on the coronary arteries. Cardiac magnetic resonance imaging demonstrated a nonhomogeneous encapsulated mass close to the right ventricle and adjacent to the ascending aorta, the pulmonary artery trunk, and the superior vena cava, with compression effects on the coronary artery. There was transmural gadolinium enhancement in the mid-to-apical anterior and inferior walls with akinesia in these segments, in favor of myocardial infarction with nonobstructive coronary arteries. The patient underwent surgical mass resection, and the pathological investigation confirmed the diagnosis of a type B1 thymoma. (Iranian Heart Journal 2022; 23(1): 214-219)
http://journal.iha.org.ir/article_142625_9941d34fe503ecb896a5e53c0cdf7b2b.pdf
2022-01-01
214
219
Myocardial infarction with nonobstructive coronary arteries
Coronary artery compression
thymoma
Rahimeh
Eskandarian
rahimeh.eskandarian@sums.ac.ir
1
Internal Medicine Research Center, Semnan University of Medical Sciences, Semnan, IR Iran.
AUTHOR
Zahra
Alizadeh Sani
d.alizadeh.sani@gmail.com
2
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohaddeseh
Behjati
dr.mohaddesehbehjati@gmail.com
3
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Roohallah
Alizadehsani
ralizadehsani@deakin.edu.au
4
Institute for Intelligent Systems Research and Innovation, Deakin University, Geelong, VIC 3216, Australia.
AUTHOR
Abbas
Khosravi
abbas.khosrav@deakin.edu.au
5
Institute for Intelligent Systems Research and Innovation, Deakin University, Geelong, VIC 3216, Australia.
AUTHOR
Saeid
Nahavandi
saeid.nahavand@deakin.edu.au
6
Institute for Intelligent Systems Research and Innovation, Deakin University, Geelong, VIC 3216, Australia.
AUTHOR
Sheikh Mohammed
Shariful Islam
shariful.islam@deakin.edu.au
7
Institute for Physical Activity and Nutrition, Deakin University, Melbourne, Australia.
LEAD_AUTHOR
Da Costa, K. Isaaz, E. Faure, S. Mourot, A. Cerisier, and M. Lamaud, "Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram; a 3-year follow-up study of 91 patients," European Heart Journal, vol. 22, no. 16, pp. 1459-1465,2001, doi:10.1053/euhj.2000.2553.
1
N. Lang and D. E. Newby, "Cardiac compression causing fatal acute ST-segment elevation myocardial infarction," QJM: An International Journal of Medicine, vol. 105, no. 9, pp. 883-885, 2011, doi: 10.1093/qjmed/hcr131.
2
D. Wright and J. C. Wain, "Acute Presentation of Thymoma With Infarction or Hemorrhage," The Annals of Thoracic Surgery, vol. 82, no. 5, pp. 1901-1904, 2006/11/01/ 2006, doi: https://doi.org/10.1016/j.athoracsur.2006.02.082.
3
Katz, S. Walsh, B. Tsang, P. McCombe, and A. Sabet, "059 Takotsubo cardiomyopathy and myasthenic crises: a case series," Journal of Neurology, Neurosurgery & Psychiatry, vol. 90, no. e7, pp. A19-A19, 2019, doi: 10.1136/jnnp-2019-anzan.51.
4
Likaj et al., "Necrotic thymoma with cardiac compression in a young lady," Journal of Cardiothoracic Surgery, vol. 8, no. 1, p. P29, 2013/09/11 2013, doi: 10.1186/1749-8090-8-S1-P29.
5
Raju, R. Nair, and K. Kaid, "INVASIVE THYMOMA CAUSING ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION," CHEST, vol. 134, no. 4, p. 1C, 2008, doi: 10.1378/chest.134.4_MeetingAbstracts.c1003.
6
X. Gue, M. Anwar, and D. A. Gorog, "A rare cause of myocardial infarction with non-obstructive coronary arteries—case report of ST-segment elevation myocardial infarction caused by a mediastinal mass," European Heart Journal - Case Reports, vol. 2, no. 1, 2018, doi: 10.1093/ehjcr/yty008.
7
ORIGINAL_ARTICLE
Candida albicans Endocarditis in a Child With Acute Lymphoblastic Leukemia: A Rare Case Report
Fungal endocarditis is rare and has a mortality rate of over 80%. It must be suspected in all immunocompromised patients with culture-negative sepsis and failure of antibiotic treatment. In such cases, echocardiography can be diagnostic.We herein describe a child with Candida albicans endocarditis presenting with heart failure, severe jaundice, and anasarca. A large obstructive mass of the tricuspid valve was detected by echocardiography, and blood culture confirmed the diagnosis. The patient was successfully treated with the surgical excision of the vegetation and intravenous liposomal amphotericin B for 3 weeks. (Iranian Heart Journal 2022; 23(1): 220-222)
http://journal.iha.org.ir/article_142627_85ec32e414ea02c2de68b34492398d6b.pdf
2022-01-01
220
222
Fungal infection
Childhood cancer
Candida endocarditis
Shahyad
Salehi-ardebili
salehi.sh@umsu.ac.ir
1
Assistant professor, Department of Cardiovascular Surgery, Seyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran.
AUTHOR
Mohammad
Radvar
dr.radvar44@gmail.com
2
Assistant professor, Department of Pediatric Disease, Shahid Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran.
AUTHOR
Behnam
Askari
askaribehnam@ymail.com
3
Associate Professor, Department of Cardiovascular Surgery, Seyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran
LEAD_AUTHOR
Saiman L, Prince A, Gersony W.M. Pediatric infective endocarditis in the modern era. Pediatr 1993;122(6):847-53
1
Nikolousis E, Velangi M. Two cases of aspergillus endo-carditis in non neutropenic children on chemotherapy for acute lymphoblastic leukaemia. Hematology Reports 2011; 3:e7:20-21.
2
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. Cancer J. Clin. 2014;64:83-103
3
Sumners JE, Johnson WW, Ainger LE. Childhood leukemic heart disease, A study of 116 hearts of children dying of leukemia. Circulation 1969;40:574-581.
4
Chaudhary N, Vishwanath M, Pahuja M, Borker A. Candida albicans endocarditis in a child with acute lymphoblastic leukemia: A dreaded complication of intensive chemotherapy. Indian J. Med. Paediatr 2013; 34(1):28-30.
5
Ariffin H , Ariffin W, Tharam S, Omar A, De-Bruyne J. Successful treatment of Candida albicans endocarditis in a child with leukemia - a case report and review of the literature. Singapore Med J. 1999; 40(8):533.
6
ORIGINAL_ARTICLE
Vascular Thromboembolism is a Grave Complication of COVID-19
There is ample evidence that the coronavirus can cause fatal blood clots. Angiotensin-converting enzyme 2 (ACE2) receptors act as a gateway for the coronavirus to enter the body and facilitate infection. ACE2 receptors are scientifically linked to disease severity in smokers because nicotine is thought to affect ACE2 expression in different ways.
Patients admitted with severe COVID-19 infection with high levels of factor V Leiden are prone to serious damage from blood clots such as deep vein thrombosis or pulmonary embolism.
Damage to the vascular endothelium is a complication that can be caused by the coronavirus. It can cause vascular clots, in the formation of which factors such as age, sex, blood type, and underlying diseases are effective. Thrombotic events, especially venous thrombosis, following COVID-19 infection have already been described; nonetheless, data are scarce on arterial thrombosis.
Herein we report 4 cases of COVID-19 infection complicated by arterial thrombosis. (Iranian Heart Journal 2022; 23(1): 223-227)
http://journal.iha.org.ir/article_142628_5203bd9395dd969e67c8a8624465ad81.pdf
2022-01-01
223
227
COVID-19
Arterial thrombosis
echocardiography
Mahmood
Monfared
m_beheshti_m@yahoo.com
1
Modarres Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Alireza
Farzin
alirezaomidi@sbmu.ac.ir
2
Modarres Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Manouchehr
Hekmat
hekmatdr@yahoo.com
3
Modarres Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Zahra
Ansariaval
zahraansariaval@gmail.com
4
Modarres Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Azadeh
Heidarpour
azadeh.heidarpour@yahoo.com
5
Tehran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
giuseppe rescigno,MD FETCS, Michael fistenberg,MD,igor rudez,MD,et al. a case of postoperative COVID-19 infection after cardiac surgery. Surgery, Dubrava University Hospital, Zagreb, Croatia. The Heart Surgery Forum #2020-3011 23 (2), 2020 [Epub April 2020]
1
Azhar Hussain MRCS . Habib Khan FRCS(CTh), Neil Roberts FRCS(CTh), Aung Oo FRCS(CTh). Cardiac surgery in patients with confirmed COVID‐19 infection: Early experience. 12 June 2020. https://doi.org/10.1111/jocs.14657
2
Isaac Cheruiyot, Vincent Kipkorir, Brian Ngure, et al. Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review. Ann Vasc Surg. 2020 Aug 28.
3
BalrajSingh,1RagiaAly,2ParminderKaur3,et al. COVID-19 Infection and Arterial Thrombosis: Report of Three Cases. https://doi.org/10.1016/j.avsg.2020.08.115
4
kaur, f.qaqa, a.rahimi,et al.acute upper limb ischemia in a patientwith COVID-19 .hematol oncol stem cel ther(2020)
5
Ryan L. Hoiland, Nicholas A. Fergusson, Anish R. Mitra, and et al.The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv (2020) 4 (20): 4981–4989.
6
Manouchehr Hekmat 1, Zahra Ansari Aval 2, *, Alireza Omidi Farzin and et al.COVID-19 Complicated by Massive Acute Pulmonary Embolism: A Case Report. Iranian Red Crescent Medical Journal: 22 (6); e105958. July 12, 2020
7
ORIGINAL_ARTICLE
Radiation-Induced Valvulopathy
Cardiovascular disease and cancer are the 2 leading causes of morbidity and mortality in the world. Radiation to the mediastinum is a key component of treatment for numerous neoplasms, including Hodgkin’s lymphoma and breast cancer. Improvements in oncological treatments have increased the number of survivors, some of whom may suffer from adverse cardiovascular effects due to radiation therapy. 1, 2
The delayed detrimental cardiovascular effects of such radiotherapy protocols have been recognized more recently, largely due to the latency of presentation. 3 Because of the increased life expectancy of these patients, healthcare providers are witnessing an increasing number of long-term side effects of these treatments. Mediastinal radiotherapy is known to cause valvular disease, pericarditis, coronary artery disease, and cardiomyopathy. 4
We herein describe a patient who developed radiation-induced valvulopathy with the typical presentation of radiation-induced heart disease 8 years after a left-sided mastectomy and receiving chemotherapy and radiotherapy for breast cancer. (Iranian Heart Journal 2022; 23(1): 228-232)
http://journal.iha.org.ir/article_142629_62433f625e235348dc3c22142f536985.pdf
2022-01-01
228
232
Radiation-induced heart disease (RIHD)
breast cancer
Cancer treatment
Parisa
Seilani
parisa_411@yahoo.com
1
Echocardiography fellowship assistant, department of echocardiography, Rajaie cardiovascular medical and research center,Iran university of medical science
LEAD_AUTHOR
Azin
Alizadehasl
alizadeasl@gmail.com
2
MD, FACC, FASE Professor of Cardiology, Echocardiologist, Head of Cardio-Oncology Department and Research Center, Rajaie Cardiovascular Medical &amp;amp; Research Center, Tehran, Iran.
AUTHOR
hossein
kamranzadeh fumani
dr.kamranzadeh@gmail.com
3
department of internal medicine,school of medicine, hematology-oncology and stem cell transplantation research center, Shariati hospital tehran university of medical sciences
AUTHOR
Maryam
Moradian
maryam_moradian2008@yahoo.com
4
department of pediatric cardiology,rajaie cardiovascular and medical and research center,iran university of medical science
AUTHOR
Mina
Ghorbanpoor
minaghorbanpoor2020@gmail.com
5
cardiology resident,Rajaie cardiovascular medical and research center,iran university of medical science
AUTHOR
Seyed Ehsan
Parhizgar
separhizgar@gmail.com
6
Cardiology resident,Rajaie cardiovascular medical and research center, Iran university of medical science
AUTHOR
Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart Disease. Heart. 2016; 102(4):269-276.
1
Umanzor E, Enríquez M, Caldentey G, San Antonio R, Paré C. Radiation-Induced Cardiac Valve Disease.The American Journal of Medicine.2017;130(3):99-100
2
Hada N, McGregor CG, Danielson GK, et al. Coronary artery bypass grafting in patients with previous mediastinal radiation therapy. J Thorac Cardiovasc Surg. 1999.117:1136-1342.
3
Mishra T, Ahmed A, Shokr M, Rashed A, S. Yassin A, Kottam A. Early-Onset Bilateral Severe Valvular Regurgitation After Mediastinal Radiotherapy in Hodgkin Lymphoma Survivors: Should We Screen Prior to 10 Years After Mediastinal Radiotherapy? Ochsner Journal.2019. 19:252–255.
4
Cozzarín A, Cianciulli T, Saccheri M, et al. Severe mitral regurgitation after radiotherapy.Echocardiography. 2014.31(2):37-40.
5
Desai M, Jellis C, Kotecha R, Douglas, et al. Radiation Associated Cardiac Disease. JACC: Cardiovascular imaging. 2018:11(8):1132-1149.
6
Khorgami, MR, Moradian, M, Omidi, N, et al. Management of cardiovascular disorders in patients with Noonan Syndrome: a case report. J Tehran Heart Cent 2017; 12: 184–187.
7
Anita Sadeghpour, Azin Alizadehasl. The Right Ventricle: A Comprehensive Review From Anatomy, Physiology, and Mechanics to Hemodynamic, Functional, and Imaging Evaluation.
8
Majid Kiavar, Rasoul Azarfarin, Ziae Totonchi, Fatemeh Tavakoli, Azin Alizadehasl , Mitra Teymouri. Comparison of Two Pain Assessment Tools, “Facial Expression” and “Critical Care Pain Observation Tool” in Intubated Patients After Cardiac Surgery. Anesth Pain Med. 2016; 6(1):e61541. doi:10.5812/aapm.33434.
9
Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949-1955.
10
Handa N, McGregor CG, Danielson GK, et al. Valvular heart operation in patients with previous mediastinal radiation therapy. Ann Thorac Surg.2001; 71:1880-1884.
11
ORIGINAL_ARTICLE
Left Atrial Myxoma With Atypical Echocardiographic Features
Accurate diagnoses of cardiac masses constitute a challenge to the cardiologist. Echocardiography plays an essential role, but differentiating between benign and malignant masses that may mimic the features of each other may not be easy by echocardiography. Myxomas are primary benign tumors of the heart with typical echocardiographic features that are generally found in certain locations in the heart. Nonetheless, they are occasionally found in atypical locations in the heart chambers and echocardiographic features mimicking malignant tumors. Myxomas may present with obstructive, embolic, and constitutional symptoms, or they might be found incidentally based on the tumor size and location. Herein, we describe a 78-year-old man with a cardiac mass with echocardiographic features inconsistent with a benign tumor, although further evaluation confirmed it as a myxoma. Benign or malignant cardiac masses could mimic the typical imaging features of each other, and the diagnosis should be based on pathologic findings. (Iranian Heart Journal 2022; 23(1): 233-236)
http://journal.iha.org.ir/article_142630_4dbf3915cc742100aa4fdb242f5a9d06.pdf
2022-01-01
233
236
Cardiac mass
Myxoma
echocardiography
Imaging
Azin
Alizadehasl
alizadeasl@gmail.com
1
Echocardiography and Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Mohammad Javad
Alemzadeh-Ansari
mj.aansari@gmail.com
2
Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Atousa
Mostafavi
mostafavi.atoosa@gmail.com
3
Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Sedigheh
Saedi
sedsaedi@gmail.com
4
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hossein
Kamranzade Fumani
dr.kamranzade@gmail.com
5
Department of Internal Medicine, School of Medicine Hematology-Oncology and Stem Cell Transplantation Research Center Shariati Hospital Tehran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Tahereh
Saedi
taherehsaedi80@gmail.com
6
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
LEAD_AUTHOR
Hoffmeier A, Sindermann JR, Scheld HH, Martens S. Cardiac tumors—diagnosis and surgical treatment. Deutsches Ärzteblatt International. 2014 Mar; 111(12):205.
1
Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF. Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences; 2018 Jan 9.
2
Sadeghpour A, Alizadehasl A. The right ventricle: a comprehensive review from anatomy, physiology, and mechanics to hemodynamic, functional, and imaging evaluation. Arch Cardiovasc Imaging. 2015 Nov 1; 3(4):e35717.
3
Cohen R, Singh G, Mena D, Garcia CA, Loarte P, Mirrer B. Atrial myxoma: a case presentation and review. Cardiology Research. 2012 Feb; 3(1):41.
4
Kalçık M, Bayam E, Güner A, Küp A, Kalkan S, Yesin M, Gürsoy MO, Gündüz S, Karakoyun S, Özkan M. Evaluation of the potential predictors of embolism in patients with left atrial myxoma. Echocardiography. 2019 May; 36(5):837-43.
5
Yoo M, Graybeal DF. An echocardiographic-confirmed case of atrial myxoma causing cerebral embolic ischemic stroke: a case report. Cases Journal. 2008 Dec 1; 1(1):96.
6
Keeling IM, Oberwalder P, Anelli-Monti M, Schuchlenz H, Demel U, Tilz GP, Rehak P, Rigler B. Cardiac myxomas: 24 years of experience in 49 patients. European journal of cardio-thoracic surgery. 2002 Dec 1; 22(6):971-7.
7
Kawall J, Seecheran R, Seecheran V, Persad S, Maharaj S, Seecheran NA. Medical management of a suspected atrial myxoma in a nonagenarian. SAGE Open Medical Case Reports. 2020 Jul;8:2050313X20933484.
8
Vasquez A, Sethi G, Maximov M, Marcus FI. Atrial myxomas in the elderly: a case report and review of the literature. The American journal of geriatric cardiology. 2004 Jan; 13(1):39-44.
9
Kim JT, Baek WK, Kim KH, Yoon YH, Kim DH, Lim HK. A primary cardiac sarcoma preoperatively presented as a benign left atrial myxoma. Yonsei medical journal. 2003 Jun 1; 44(3):530-3.
10
ORIGINAL_ARTICLE
Chronic Pericardial Hematoma With A Cystic-Like Appearance
Intrapericardial hematomas are mostly found in association with traumas, cardiac surgical operations, and coronary interventions. In the case of open-heart surgeries, intrapericardial hematomas usually resolve without complications. However, in rare cases, they could be chronic or mimic the features of other lesions. We herein introduce a case of pericardial hematoma late after coronary artery bypass surgery with a cystic-like appearance. (Iranian Heart Journal 2022; 23(1): 237-239)
http://journal.iha.org.ir/article_142631_de5967fc8d7912cf3bdadb73386eb13c.pdf
2022-01-01
237
239
PERICARDIAL CYST
hematoma
Coronary artery bypass surgery
Khadije
Mohammadi
khma_65@yahoo.com
1
Cardiovascular Research Center, Kerman University of Medical Sciences, Kerman, IR Iran.
LEAD_AUTHOR
Mozhgan
Parsaei
paraseemozhgan@yahoo.com
2
Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hamidreza
Pouraliakbar
hamidpou@yahoo.com
3
Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
Hamed
Fattahi neisiani
hamedfattahi@gmail.com
4
Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
AUTHOR
KOÇ M, KORKMAZ H. Intrapericardial Organized Hematoma: A Rare Complication After Coronary Surgery, Radiological Findings. Turkiye Klinikleri J Cardiovasc Sci. 2009;21(3):502-4. 2003 May 1; 75(5):1629-31.
1
Hirai S, Hamanaka Y, Mitsui N, Isaka M, Kobayashi T. Chronic expanding hematoma in the pericardial cavity after cardiac surgery. Ann Thorac Surg. 2003 May 1; 75(5):1629-31.
2
Ueda H, Baba H, Ondo K. Treatment of chronic expanding hematoma of the thorax with median sternotomy. Gen Thorac Cardiovasc Surg. 2013 Aug 1; 61(8):466-8.
3
Schlömicher M, Haldenwang PL, Reichert J, Moustafine V, Bechtel M, Strauch JT. Chronic pericardial hematoma with suppression of the right ventricle: a rare complication of a coronary artery aneurysm. Thorac Cardiovasc Surg Rep. 2014 Dec; 3(1):27.
4
Marques A, Fazendas P, João I, Gomes AC, Pereira H. Pericardial hematoma mimicking pericardial abscess. Echocardiography. 2020 Apr; 37(4):649-51.
5
Patel J, Park C, Michaels J, Rosen S, Kort S. Pericardial cyst: case reports and a literature review. Echocardiography. 2004 Apr; 21(3):269-72.
6
Komodromos T, Lieb D, Baraboutis J. Unusual presentation of a pericardial cyst. Heart Vessels. 2004 Jan 1; 19(1):49-51.
7